



Interrupting the Conversation: Implications for Crosstalk Between Viral and Bacterial Infections in the Asthmatic Airway

Jodie Ackland¹, Alastair Watson^{1,2,3}, Tom M. A. Wilkinson^{1,2,4} and Karl J. Staples^{1,2,4*}

¹ Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, Southampton, United Kingdom, ² NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ³ College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁴ Wessex Investigational Sciences Hub, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, United Kingdom

Asthma is a heterogeneous, chronic respiratory disease affecting 300 million people and is thought to be driven by different inflammatory endotypes influenced by a myriad of genetic and environmental factors. The complexity of asthma has rendered it challenging to develop preventative and disease modifying therapies and it remains an unmet clinical need. Whilst many factors have been implicated in asthma pathogenesis and exacerbations, evidence indicates a prominent role for respiratory viruses. However, advances in culture-independent detection methods and extensive microbial profiling of the lung, have also demonstrated a role for respiratory bacteria in asthma. In particular, airway colonization by the Proteobacteria species Nontypeable *Haemophilus influenzae* (NTHi) and *Moraxella catarrhalis* (Mcat) is associated with increased risk of developing recurrent wheeze and asthma in early life, poor clinical outcomes in established adult asthma and the development of more severe inflammatory phenotypes. Furthermore, emerging evidence indicates that bacterial-viral interactions may influence exacerbation risk and disease severity, highlighting the need to consider the impact chronic airway colonization by respiratory bacteria has on influencing host responses to viral infection. In this review, we first outline the currently understood role of viral and bacterial infections in precipitating asthma exacerbations and discuss the underappreciated potential impact of bacteria-virus crosstalk in modulating host responses. We discuss the mechanisms by which early life infection may predispose to asthma development. Finally, we consider how infection and persistent airway colonization may drive different asthma phenotypes, with a view to identifying pathophysiological mechanisms that may prove tractable to new treatment modalities.

Keywords: asthma, bacteria, virus, co-infection, exacerbation, inflammation, early-life

INTRODUCTION

Asthma is a complex and heterogeneous disease of the airways characterized by episodic and reversible airway obstruction, bronchial hyper-responsiveness, and airway inflammation that affects over 300 million people globally (1). Asthma is diagnosed by assessment of airway reversibility performed by spirometry before and after bronchodilator use (2). Allergic sensitivities

OPEN ACCESS

Edited by:

Sun Ying,
Capital Medical University, China

Reviewed by:

Amali E. Samarasinghe,
University of Tennessee Health
Science Center (UTHSC),
United States
Manali Mukherjee,
McMaster University, Canada

*Correspondence:

Karl J. Staples
k.staples@soton.ac.uk

Specialty section:

This article was submitted to
Asthma,
a section of the journal
Frontiers in Allergy

Received: 09 July 2021

Accepted: 20 September 2021

Published: 26 October 2021

Citation:

Ackland J, Watson A, Wilkinson TMA
and Staples KJ (2021) Interrupting the
Conversation: Implications for
Crosstalk Between Viral and Bacterial
Infections in the Asthmatic Airway.
Front. Allergy 2:738987.
doi: 10.3389/falgy.2021.738987

are a risk factor for asthma development and can be tested for using the skin prick test, which measures reactions to a variety of common environmental allergens (3), or measuring serum levels of IgE (4). However, non-allergic (or non-atopic) forms of asthma can develop following exposure to a non-allergic environmental trigger. As such, clinically defining and treating asthma is complex due to a number of clinical asthma phenotypes displaying different disease pathologies, which are further underpinned by multiple inflammatory endotypes (5, 6).

Asthma phenotypes are broadly split into allergic and non-allergic (5), with allergic asthma being the most widely recognized form and implicated in 50–80% of asthma cases (7). Allergic asthma is induced by common environmental allergens including house dust mite, grass and tree pollen, mold and ragweed and is characterized by type 2 (T2) inflammation (5). T2 inflammation is driven by cytokines such as interleukin (IL)-4, IL-5, and IL-13 released by T helper (Th) 2 cells which increase the recruitment and survival of eosinophils (**Figure 1**). T2 inflammation promotes the pathophysiological features of eosinophilic asthma including increased basement membrane thickness and corticosteroid responsiveness (5, 6, 8–10). However, an increasing number of studies demonstrate evidence of T2-low inflammation in some asthma patients (11, 12). T2-low responses are associated with T1 or T17 inflammation, increased inflammasome responses and corticosteroid insensitivity [**Figure 1**; (13)]. In contrast to T2-high and eosinophilic inflammation, a major feature of T2-low inflammation is increased neutrophil infiltration. Neutrophils are now understood to play a significant role in asthma and are associated with severe asthma phenotypes, severe airflow obstruction, steroid-resistance and increased presence of potentially pathogenic bacteria (14–16). However, there are individuals who exhibit high levels of both eosinophils and neutrophils, designated as a mixed granulocytic phenotype, which is also associated with more severe asthma and poor responses to current treatments, despite the presence of eosinophils (17).

The multifactorial nature of asthma is such that therapies concentrate on decreasing symptoms rather than disease cure. The most commonly used therapies include inhaled/oral corticosteroids and leukotriene modifiers to control airway inflammation and bronchodilators such as β_2 -agonists or anticholinergics for immediate relief of asthma symptoms (18). However, even patients with good treatment adherence can still experience exacerbations of their asthma symptoms (19). An asthma exacerbation is characterized by a worsening of symptoms and can be graded in severity as mild, moderate, severe or life-threatening (20). Symptoms include wheeze, shortness of breath and chest tightness and are induced by airway inflammation, resulting in airflow obstruction and increased airway responsiveness (2, 21). With ~65,000 hospital admissions yearly in the UK, exacerbations contribute to the considerable financial and logistical burden of asthma on the health care system, with the added economic impact due to lost productivity of workers (22). Exacerbations can also enhance disease progression by increasing the rate of lung function

decline and thus asthma severity (23–25), with some more severe forms of asthma resistant to even high doses of steroid treatment (10).

The future of asthma treatment and management is moving towards modulating specific components of the immune system involved in asthma pathogenesis by use of monoclonal antibodies targeting specific inflammatory mediators (26, 27). As such, a number of therapeutics aim to reduce the number of eosinophils and T2 cytokines using anti-IL5 antibodies. However, the mechanisms driving efficacy of anti-IL5 antibodies is unclear: although blood eosinophils are reduced, the impact on airway responses, such as sputum eosinophils, exacerbation frequency, and pulmonary function is varied (28). Importantly, even individuals treated with the anti-IL5R monoclonal antibody, benralizumab, have been reported to experience exacerbations that were predominantly non-eosinophilic in nature and associated with infection (29). Thus, given the mixed outcomes of targeting IL-5/eosinophils and the potential for the involvement of other inflammatory immune cells in asthma pathogenesis, there remains an unmet need for better asthma treatments, particularly in terms of exacerbation prevention (30). Triggers of asthma exacerbations include air pollution, cigarette smoking, allergens and respiratory tract infection (RTI) with virus and bacteria (1). Interactions between these triggers likely occur, with the underlying host susceptibility also playing a role in exacerbations, which renders it challenging to ascertain the exact mechanisms and interplay involved in exacerbations and develop effective therapeutics. Despite the importance of all of these triggers in asthma pathogenesis, in this review we focus on the role of bacteria and viruses and their crosstalk, with the role of other environmental factors recently reviewed elsewhere (31, 32).

Respiratory tract viral infections are also linked to early life asthma development. The advent of non-culture-based methods of bacterial detection, such as 16S rRNA sequencing, has increased appreciation for the role of potentially pathogenic bacteria in asthma development and pathogenesis (**Figure 2**). Airway colonization by potentially pathogenic bacteria within 1 month of life is suggested to predispose individuals to asthma (33), indicating that modulation of airway immunity may occur even prior to respiratory tract viral infections. Indeed, bacteria-virus co-infection of the airway results in more severe exacerbations and hospital readmission of individuals with chronic respiratory disease (34). These observations suggest an underappreciated crosstalk is occurring during bacteria-virus co-infections in the airway.

Here we will review the currently understood role of infection in three aspects of asthma: (i) asthma exacerbations, (ii) early life development of asthma, and (iii) established asthma and inflammatory phenotypes. We will discuss the emerging evidence of crosstalk between bacteria and viruses and the host, with a particular focus on how co-occurrence of pathogens may impact asthma pathogenesis and inflammatory phenotypes. Finally, we will discuss how our increasing appreciation for the co-occurrence of certain respiratory pathogens and their crosstalk may reveal novel treatment modalities to improve outcomes for individuals with asthma.




FIGURE 1 | Overview of inflammatory pathways in asthma. Inflammation in asthma is defined as Type (T)2-high or T2-low. T2-high inflammation is characterized by T2 cytokines such as interleukin (IL)-4, IL-5, IL-9, and IL-13. These cytokines can be released by T helper (Th) 2 cells or innate lymphoid group 2 cells (ILC2s). Th2 cells are stimulated by IL-4 whereas ILC2s are stimulated by IL-25, IL-33, or Thymic Stromal Lymphopoietin (TSLP). The T2 cytokines promote the cellular features of T2 inflammation including eosinophil recruitment and activation, B cell proliferation, IgE class switching, and mast cell activation. Although T2 inflammation is generally responsive to steroids, it results in the classical pathophysiological features of asthma including airway hyperresponsiveness, remodeling, and eosinophilia. T2-low responses are often associated with T1 or T17 inflammation. T1 inflammatory responses are regarded as important for defense against intracellular pathogens and are driven by Th1 cells, which are activated upon stimulation by either IL-27 or IL-12. Th1 cells release IL-2, IFN- γ , or TNF- α which activates macrophages and promotes microbial killing. Macrophages also participate in positive feedback through production of IL-12/IL-18, CXCL9, CXCL10, and CXCL11 to amplify T1 inflammation. T17 responses are induced through IL-23 stimulation of Th17 cells. Th17 cells release IL-21 and IL-17 which can either autoregulate Th17 cell differentiation or can act upon epithelial cells or macrophages to release IL-1 β , IL-8, CXCL1, and IL-6 to promote neutrophil recruitment and activation. T17 responses are associated with the neutrophilic asthma phenotypes, inflammasome activation, and steroid-resistance in asthma. Created using BioRender.com.

ASTHMA EXACERBATIONS: THE ROLE OF INFECTION

The role of viral infection in asthma exacerbations has been known for decades, with early studies showing associations between respiratory pathogens and asthma attacks (35), with

experimental rhinovirus (RV) inoculation of volunteers inducing airway hyperresponsiveness providing evidence for viral infection contributing to exacerbations (36, 37). A systematic review by Papadopoulos et al., found 9 viruses associated with exacerbations of asthma, with virus prevalence differing between adults, children (6–17 years old) and infants (<6 years old) (38).




FIGURE 2 | Overview of the impact of infection in early life asthma development, on chronic inflammation in established asthma and during asthma exacerbations. The development and stability of the microbiome in early life is associated with allergen exposure, mode of delivery, feeding method, and antibiotic use. The composition of the microbiome is associated with the number of RTIs during infancy, which is subsequently associated with increased risk of asthma development in later life. Microbial dysbiosis resulting in microbiome profiles enriched in Proteobacteria particularly is associated with development of asthma and aberrant immune responses in later life. During established asthma, chronic colonization of the airway by Proteobacteria is associated with modulation of airway inflammation. NTHi persistent airway colonization causes inflammatory responses switching to T17, neutrophilic inflammation, increased inflammasome activation, which is linked to increased steroid-resistance. As a possible consequence of chronic bacterial colonization, baseline immunity in asthma is altered, including decreased antiviral immunity (IFN responses) and macrophage function (phagocytic ability). Viral infection is established due to delayed antiviral responses, which causes increased asthma symptoms, resulting in a virally driven exacerbation. Different viruses cause different disease pathology (e.g., increased cellular cytotoxicity following IAV infection compared to RV) and induction of T2-low (IAV) or T2-high (RV) responses. Bacterial infection also causes exacerbations and are likely contributors to exacerbation symptoms following viral infection, as bacterial outgrowth occurs due to impaired phagocytosis and macrophage immune response sensitization induced by viral infection. Again, different bacteria induce different responses, with Mcat reported to induce a mixed T1/2/17 response, whereas NTHi drives a T1/T17 pro-inflammatory response. Co-infection can augment inflammation and asthma symptoms, which may impact on treatment failure/success during exacerbation. Created using BioRender.com.

RV is the most common virus detected during an exacerbation in both children (55%) and adults (29%) (38), with detection of RV up to 5 days prior, being found to be significantly associated with the development of an exacerbation (39). However, the exact causative role of viral infection in asthma exacerbations remains unclear, with other studies demonstrating no changes in asthma symptoms following viral challenge (40, 41).

Furthermore, the development of culture-independent methods has advanced our ability to detect respiratory pathogens that are difficult to culture, resulting in an expansion of our knowledge of the pathogens present in the airways and associated with exacerbations. For example, the presence of RV-C was likely previously overlooked due to difficulties in growing and culturing RV-C *in vitro* (42), but is now suggested to be the RV strain associated with more severe illness (43). However, the majority of patients presenting with asthma exacerbations are not screened using multiplex PCR viral detection systems meaning that the true association of different viral pathogens with asthma exacerbations is

difficult to interpret. Numerous bacterial pathogens, other than the original atypical bacterial pathogens *Mycoplasma pneumoniae* and *Chlamydia pneumoniae* (44), are now implicated in asthma, including *Haemophilus influenzae*, *Moraxella catarrhalis* (Mcat), *Streptococcus pneumoniae*, *Haemophilus parainfluenzae*, *Klebsiella pneumoniae*, and *Bordetella pertussis* (45–47). Studies have consistently identified enrichment of Proteobacteria in asthma (48) and have shown *H. influenzae* and Mcat to be associated with clinical outcomes. *H. influenzae* is associated with poor asthma control (49), steroid-resistance (45, 50), neutrophilic inflammation (45, 51, 52), and increased disease severity (16, 49). In contrast, Mcat is associated with the induction of mixed inflammatory phenotypes (45, 51, 53), loss of asthma control in children (54), and increased number of exacerbations in children (55). As such, this review will mainly focus on these two clinically important Proteobacteria, as well as three viruses of interest: RV, influenza, and respiratory syncytial virus (RSV).




FIGURE 3 | Factors contributing to infection-induced exacerbations. The role of infection in exacerbations are likely to be multifactorial, with several host, pathogen, and environmental factors impacting on the contribution of infection to an exacerbation. Each factor may be multi-directional and directly or indirectly impact on another factor, highlighting the complex mechanisms involved in exacerbations. Created using BioRender.com.

Mechanisms Contributing to Infection-Induced Asthma Exacerbations

Despite epidemiological studies demonstrating associations between infection and asthma exacerbations, the exact mechanisms by which these different pathogenic triggers drive exacerbations remain unclear. As detection of pathogens during exacerbation do not prove causation, it is important to consider how other factors may contribute to exacerbations (**Figure 3**). The multifactorial nature of asthma is such that the underlying atopic status, timing of allergen exposure or asthma severity may influence the host response to infection and account for differences observed in experimental challenge or observational studies. For example, influenza infection causes increased epithelial cell lysis compared to RV infection (21), but the presence of an atopic environment was shown to increase RV cytotoxicity (56) and be protective against influenza A infection (57, 58). The timing of allergen exposure and viral challenge also appears to influence outcomes. Sensitization and exposure to high allergen levels followed by viral exposure increases the risk of hospital admission (59), whereas individuals challenged with allergen after RV infection demonstrated higher levels of allergic responses compared to non-allergic individuals challenged with RV (60). As such, differences in clinical or experimental study outcomes may be due to a number of host or pathogen factors including genetics, allergen sensitization, asthma endotype, comorbidities, age, experimental timing and

dosing, seasonality, and viral strain. Nonetheless, a study using omalizumab, an anti-IgE monoclonal antibody, was found to reduce exacerbations even during seasonal peaks (61), providing evidence for allergen-viral interactions in exacerbations.

Different respiratory pathogens, even different strains of the same pathogen, induce distinct responses (62–64). However, the underlying inflammatory environment and host immune responses may further influence infection outcomes (**Figure 4**). Investigations building on experimental challenge studies have identified a number of potential host impairments which may contribute to infection-induced exacerbations. These include ciliary dysfunction, ciliostasis, mucus hypersecretion (65), goblet cell hyperplasia (66–70), altered and dysregulated baseline inflammatory gene expression (71), impaired antiviral responses (72), delayed interferon responses (73), decreased levels of the innate immune surfactant protein (SP)-D (74), altered macrophage phenotype (75), and decreased macrophage phagocytosis (76, 77). The exact mechanisms of how each individual pathogen contributes to an asthma exacerbation is multifactorial and is likely dependent on pathogen strain/subtype and a myriad of host factors. These factors become even more complicated when we consider the potential of bacteria-virus interactions with the host and how these may influence the development of exacerbations. We will next consider how bacteria-virus crosstalk during co-infection may precipitate asthma exacerbations.




FIGURE 4 | Summary of the diverse potential mechanisms contributing to and influencing infection-induced exacerbations. **(A)** The role of bacteria in exacerbations are not well-known but inflammatory profiles associated with exacerbations appear to be pathogen dependent. (i) NTHi infection results in upregulation of pro-inflammatory mediators and is associated with persistent infection, neutrophilic inflammation and steroid-resistance. Chronic NTHi airway colonization may occur as a result of macrophage impairment in phagocytosis. (ii) On the other hand, exacerbations with Mcat are associated with acquisition of a new Mcat strain and is associated with both neutrophilic and eosinophilic inflammation. **(B)** Viral induced exacerbations can induce the hallmarks of asthma exacerbations through upregulation of T2 responses. (iii) Epithelial cells and macrophages contribute to IL-33, IL-25, and TSLP release, resulting in ILC2 or Th2 release of IL-4, IL-5, and IL-13 to upregulate eosinophils and B cells, which produce IgE and subsequently activate mast cells, all of which induce airway hyperresponsiveness, remodeling, and mucus hypersecretion. (iv) Conversely, some viruses have been shown to induce IL-8, CXCL5, and CXCL1 release, resulting in neutrophilic inflammation and epithelial damage via neutrophil production of NETs. (v) Influenza infection can impact on macrophage function or result in macrophage depletion, which along with mucus plugging, and may render the airway susceptible to persistent bacterial infection, and may further act to exacerbate airway inflammation. Underlying host factors such as (vi) impaired host antiviral immunity may result in an altered baseline immune profile that contributes to a dysregulated host response, whereas (vii) allergen sensitization or exposure may synergistically augment inflammation and increase cell lysis and damage during viral infection. Created using BioRender.com.

Double Trouble? The Role of Co-infections in Asthma Exacerbations

Bacterial and viral airway co-infections in chronic respiratory disease are an important clinical consideration due to individuals suffering from more severe illness, increased exacerbation risk and increased hospital readmissions (34, 78, 79). *H. influenzae* in particular has been found to be co-detected with the three main etiological viral agents of asthma exacerbations, influenza, RV, and RSV, resulting in increased disease severity and likelihood of viral infection when *H. influenzae* is present (46, 55, 79–83). Notably, associations between *H. influenzae* and RV in the airway are not limited to asthma, with longitudinal studies in COPD demonstrating the presence of both NTHi and RV associating

with decreased lung function, increased exacerbation risk and increased airway inflammation (84, 85).

In contrast, Kloepfer et al. analyzed the impact of RV-bacteria co-infection in children and found that *H. influenzae* did not associate with increased respiratory symptoms. Instead, carriage of Mcat was more significantly associated with increased symptoms and asthma exacerbations, with no associations between pathogen and atopic status (78). This association between Mcat and RV in asthmatic children may be due to similarities in the timing of RV and Mcat circulation, as well as age-dependent host factors. As the seasonal pattern of Mcat coincides with RV, it is possible that RV-Mcat or RV-host interactions may promote Mcat pathogenesis in children.

Modulation of Host Cell Surfaces

Several studies have attempted to elucidate the mechanisms underlying bacteria-virus crosstalk during co-infection using various combinations of model systems, respiratory pathogens, and infection protocols. Modulation of host cellular surfaces by pathogens may increase the ability of other pathogens to adhere to airway cells and establish infection (86). *In vitro* studies have shown that the main cellular receptor for RV, ICAM-1, is upregulated following infection of epithelial cells and monocytes by NTHi (87) and Mcat (88) and is also utilized by NTHi for adherence and invasion (89). Increased RV infection following pre-incubation of epithelial cells with NTHi, was associated with NTHi-mediated upregulation of ICAM-1 (90).

Similarly, both IAV and NTHi exploit the presence of sialic acids present on host cells to facilitate attachment and entry into host cells (91–94). IAV strains preferentially bind to α 2,6-linked sialic acid residues (91), whilst NTHi can bind to α 2,6- or α 2,3-linked sialic acid residues depending on the differential expression of NTHi outer membrane proteins HMW1/2 or Hia (92–96). An intriguing concept is that the use of sialic acid by both NTHi and IAV to establish infection could in fact predispose the airway to infection by other respiratory tract pathogens such as *S. pneumoniae*, which can co-infect the airway with NTHi (97). Work using *in vitro* and *in vivo* infection models demonstrated that desialylation of epithelial cells following IAV infection resulted in increased *S. pneumoniae* adhesion to host cells (98).

Modulation of Host Immune Responses

As well as influencing pathogen adherence to the respiratory tract, co-infection also modulates host responses. Viral infection can result in a phenomenon termed immune paralysis, characterized by immunological defects such as decreased macrophage phagocytosis (99). Murine alveolar macrophages (AM) display reduced phagocytosis in response to secondary bacterial challenge a week after initial influenza virus challenge, resulting in higher bacterial burden (100). Another study reported sustained desensitization of AM lasting for several months following influenza infection, resulting in reduced chemokine production and NF- κ B activation, leading to reduced airway immune cell recruitment during secondary bacterial challenge (101). Furthermore, influenza infection of mice reduced the number of AM, increasing susceptibility to secondary *S. pneumoniae* infection (102). These impacts are not limited to influenza: RV infection of human AM also resulted in impaired pro-inflammatory cytokine release and modulation of phagocytosis capacity during subsequent AM challenge with LPS or *E. coli* bioparticles (103).

In contrast, studies have demonstrated augmented pro-inflammatory responses during co-infection, which may translate to the enhanced inflammation, increased illness severity and hospital admissions observed during asthma exacerbations (34, 78). Co-infection of epithelial cells with RV and NTHi increased release of neutrophil chemoattractants, CCL20 and CXCL8/IL-8, compared to infection with either pathogen alone (104). Frick et al. found that co-infection with NTHi and RV resulted in increased neutrophil adherence *in vitro* and leukocyte

recruitment in an airway infection murine model (87). Similarly, neutrophil infiltration was observed in a NTHi-IAV murine co-infection model, which also demonstrated increased levels of pro-inflammatory cytokines (105). Conversely, a recent study utilizing an allergic airways disease murine model reported that the microbiome structure was influenced by the allergic inflammatory environment, which in turn reduced the impact of influenza-*S. pneumoniae* co-infection (106). Consideration of disease setting and other potential underlying host factors is important; not only does the microbiome appear to influence responses to infection, but murine models of allergic airways disease have shown the presence of an atopic environment also influences infection outcomes (58).

Does the Timing of the Immune Response During Co-infection Influence Outcomes?

Although bacteria-virus interactions have historically been investigated in the context of secondary bacterial infections succeeding viral infection, our increasing knowledge of airway microbiota presence requires careful consideration of host-pathogen dynamics. Invasion and persistence within epithelial and immune cells enhances survival of both NTHi and Mcat (107–115), with airway persistence varying from days to years (85, 116–119). This chronic airway presence may modulate host immune responses and influence the progression of a subsequent viral infection. A number of *in vitro* studies have reported modulation of anti-viral responses by bacteria. Heinrich et al. found that, *in vitro*, Mcat-mediated TLR3 downregulation led to decreased secretion of interferons such as IFN- β and IFN- λ , resulting in increased susceptibility of epithelial cells to a subsequent RV infection (120). In contrast, NTHi infection upregulated TLR3 receptor expression in airway epithelial cells prior to RV infection. However, as NTHi also upregulated ICAM-1 expression, levels of RV attachment to cells increased, resulting in synergistic IL-8 release (121). In a separate study, NTHi infection also enhanced epithelial cell TLR7 expression and type I IFN responses. However, this study did not assess whether this modulation of anti-viral immunity influenced a subsequent viral response (122). Importantly, TLR7 expression by AMs from severe asthma is reduced (123). As such, NTHi-mediated upregulation of type I IFN responses *via* TLR7 may not be recapitulated in the severe asthmatic airway.

Unraveling host-pathogen interactions outside of the lung environment is complex and challenging, highlighting the importance of translating *in vitro* and murine *in vivo* studies into human disease settings. Human challenge models may help us better reconcile observations and associations from clinical cohort studies and experimental models. For example, a recent eloquent study by Habibi et al., identified an association between a neutrophil transcriptomic signature with increased susceptibility for RSV symptomatic infection using experimental RSV nasal inoculation of healthy volunteers (124). Thus, the presence of bacteria such as NTHi, which is associated with a neutrophilic phenotype, may predispose individuals to symptomatic viral infection, which may consequently result in development of an asthma exacerbation. Indeed, a study by De

Steenhuijsen Piters et al., found that children with *H. influenzae*-dominant microbiomes were more likely to be hospitalized with RSV-induced bronchiolitis and was associated with neutrophil and macrophage transcriptomic signatures (125).

However, asthma is heterogeneous and caution must be used when interpreting results from single clinical studies in humans. Various differences between study cohorts may impact on conclusions, including factors such as age, underlying inflammatory phenotype, current treatment, and microbiome structure. For example, varying clinical cut offs for eosinophilic and neutrophilic inflammation (126, 127), as well as the use of molecular markers of T2 inflammation (*CLCA1*, *SERPINB2*, and *POSTN*) (53) can be used to stratify patients. The diverse nature of asthma patients may account for the conflicting evidence of bacterial abundance and diversity in asthma (128–131), with some studies also indicating that microbiome diversity and abundance differs with T2-low/high or eosinophilic/neutrophilic inflammatory phenotypes (49, 51, 53), and steroid-responsiveness (128, 131). As such, it is important to consider how the aforementioned factors may collectively impact on study outcomes when considering the role of bacteria in asthma.

Overall, the impact of bacterial pre-exposure on host immunity and subsequent viral infection appear conflicting; the differences in the results of these studies may be due to different infection models, pathogen strains/combinations and infection protocols used. It is important to determine whether bacterial presence in the airway is a protective, causative, or contributing agent for exacerbations, or a biomarker for exacerbation risk, depending on underlying host factors. However, whilst the role of RTI in causing asthma exacerbations has been known for at least 30 years, there is now emerging evidence that RTI may also contribute to asthma development. This emerging evidence is the focus of the next section.

EARLY LIFE: THE ROLE OF INFECTION

Asthma is regarded as a hereditary trait and the use of genome-wide linkage studies of twins and families have resulted in estimates of heritability that range from 35 to 70% (132–134). Numerous candidate genes have been suggested to be associated with asthma, with Genome Wide Association Studies (GWAS) identifying asthma susceptibility loci (135, 136). However, independent GWAS do not completely overlap in their findings, likely due to differences in environmental exposures of individuals within study cohorts (137). Environmental factors play a considerable role in asthma development (Figure 2), with Thomsen et al. identifying that environmental factors explained a higher proportion of the variation in age of onset of asthma (66%) compared to genetic factors alone (34%) (133). Earlier GWAS and candidate gene association studies did not include the possibility of environmental factors interacting with host genetics, which may explain the lack of overlap between studies (137). Building on candidate gene associations and GWAS, gene-environment interaction studies may unveil novel genes that are only significant for asthma susceptibility

when combined with the appropriate environmental exposure (138). Such environmental factors include smoking, pollution, mold, farming-related exposures, dust, and respiratory tract infections (134). This section will discuss the potential role of respiratory tract infections in predisposing individuals to asthma development.

Gene-Bacteria-Virus Interactions Influencing Host Immunity in Early Life

Given that asthma is characterized by dysregulated and exacerbated immune responses, as a result of genetic-epigenetic-environmental interactions, assessing the influence of infection on host immunity has been an important area of investigation. It has been suggested that viral infection in combination with genetic predisposition increases the risk for childhood asthma development. A GWAS identified the first known asthma susceptibility locus, 17q21 (139), which is associated with childhood respiratory infection (140). Notably, investigation of this locus in two cohorts—the Childhood Origins of Asthma (COAST) birth cohort and the Copenhagen Prospective Study on Asthma in Childhood (COPSAC) birth cohort—found that responses to RV, but not RSV, were associated with 17q21; RV-stimulated PBMCs expressed higher levels of two 17q21 genes, *GSDMB* and *ORMDL3* (141). Subsequent *in vitro* investigations silencing *ORMDL3* reported attenuated pro-inflammatory responses and reduced *ICAM1* expression, providing a potential mechanistic basis for *ORMDL3* and RV susceptibility in asthma (142). Given that ICAM-1 also serves as a receptor for NTHi and is upregulated in response to NTHi presence (90), it is possible a complex interplay occurs between genetic susceptibility, chronic NTHi airway colonization and RV infection. Furthermore, recent work has identified a potential prominent role of RV-C in childhood asthma development. The RV-C entry receptor is CDHR3, the product of *CDHR3*, which was identified by Bønnelykke et al. in a GWAS to be an asthma susceptibility gene (143). The *CDHR3* gene is associated with increased RV-C detection and risk of respiratory tract illness (144), further highlighting the importance of gene-environment interactions wherein viral infection is a critical environmental exposure.

Genetic alterations may also predispose individuals to recurrent bacterial infections. The Toll Like Receptor (TLR)4 polymorphism, Asp299Gly, is associated with increased gram negative bacterial infections (145), lower cell surface TLR4 expression, and impaired TLR4-mediated lipopolysaccharide (LPS) signaling (146). Individuals carrying the Asp299Gly TLR4 polymorphism that were colonized with Mcat at 2 months or *H. influenzae* at 13 months of age were at an increased risk of asthma development (147). Stimulation of PBMCs *ex vivo* found that this particular polymorphism results in decreased LPS-induced IL-10 and IL-12 responses and was independently associated with atopic asthma (148). However, an earlier study did not find any associations between TLR4 polymorphisms and asthma (149), likely due to potential differences in cohort-specific gene-environment interactions. Indeed, Terasjarvi et al. did not find an association between TLR4 polymorphism and

asthma risk alone, but instead between TLR4 polymorphism, *H. influenzae* colonization, and asthma risk (147), highlighting the need to consider multiple host-environment factors to unravel the complex and multifaceted nature of asthma.

Viral Infection

Early studies initially identified viral infection to be significantly predictive of asthma development, resulting in a focus on early life viral infections and asthma development (150–152). In infancy, wheezing is one of the earlier predictors of asthma, heavily implicating viruses such as RV and RSV. Early work reported RV-associated wheezing during infancy was the strongest predictor for wheezing in the third year of life (151) and more severe RV infections resulting in hospitalizations during infancy were associated with asthma development (150). Retrospective studies have identified children with early life RSV infection, particularly those requiring hospitalization, to be more at risk of asthma development (153). Children who were hospitalized as a result of severe RSV bronchiolitis were shown to be at risk of developing asthma by age 18 (154). Indeed, in this Swedish study, 30% of children who developed severe bronchiolitis developed reactive airways disease by age 7 compared to just 3% of controls. Studies in animal models have shown that RSV infection can upregulate IL-4, IL-5, IL-13, and the T2 chemokine CCL17 (155). This increase in T2 cytokines was postulated by the authors to be a result of NK cell depletion and subsequent reduction of IFN γ expression by RSV. This RSV-induced switching to a T2-phenotype may explain some of this susceptibility to asthma development. Furthermore, *in vitro* work has shown decreased RSV load was associated with the epigenetic regulation of RIG-I following IFN γ priming (156). Thus, the timely development and maturation of immune responses may depend on early life pathogen exposure.

Synergistic interactions between virus and allergen exposure may also contribute to asthma development. RV or RSV induced illness in infancy is associated with subsequent wheezing, but was found to be most significantly associated in children who were sensitized when <2 years old (157). The importance of age and timing of allergen sensitization was confirmed in a separate cohort, with 65% of children sensitized by 1 year of age identified to have asthma by 13 years of age, compared to only 17% of children sensitized by 5 years of age (158). A synergistic effect of allergen exposure and viral infection was proposed following inoculation of volunteers with RV and allergen challenge, which augmented allergic airway responses compared with RV inoculation alone (60). Subsequent studies confirmed this observation, with increased risk of hospitalization associated with allergen sensitization and viral infection during exacerbations of childhood asthma (59, 159). The mechanisms underlying how virus-allergen exposure synergistically contributes to asthma development are not understood, however a murine model of RSV infection and allergen sensitization found that recurrent RSV infections of sensitized mice resulted in T2 cytokine production, increased serum IgE and airway hyperresponsiveness (160).

Although viral infections are thought to be transient and provoke an acute inflammatory response, associations between

viral infection and asthma development have prompted investigations into how viruses cause chronic inflammation. Studies have identified that, following the initial viral insult, trace amounts of virus are detectable in the lung and are associated with increased eosinophilic inflammation, airflow obstruction and lower FEV₁ (161). A murine model of chronic respiratory disease demonstrated this persistent inflammation and airway hyperresponsiveness was mediated by lung macrophages activating invariant natural killer T (iNKT) cells to release IL-13, a finding that, importantly, was also observed in a human cohort (162). Thus, viral infection in early life may initiate immunological changes that persist and precipitate asthma development.

As most children are exposed to viruses during early life, but not all children go on to develop asthma, it is likely that other co-factors are involved. Intriguingly, analysis from the COPSAC cohort found that no specific infectious trigger, but rather, the number of respiratory episodes predisposes individuals to asthma in later life (163). Studies have shown that in fact, enrichment of certain bacteria in the respiratory tract during early life is associated with recurrent RTIs and increased risk of asthma development.

The Role of Microbial Dysbiosis in Asthma Development

Our understanding of the role of bacteria in the airway is only recently being advanced due to the incorrect dogma of lung sterility, which has prevailed since the late nineteenth century. As the study of the lung microbiome is a relatively young field, it faces technical and methodological challenges, particularly given the low microbial biomass of the lung environment (164). Despite this, common lung microbiome profiles have been successfully identified, allowing for comparisons of the lung microbiome between health and disease (48, 164, 165). The dynamics of early life microbiome development are suggested to influence the maturation of host immune responses and consequently respiratory health, with childbirth delivery mode and breastfeeding associated with microbiome structure, development, and temporal stability (166–169).

One theory that attempts to explain the increased incidence of asthma during the twentieth century is the “hygiene hypothesis” (170, 171). This theory, backed by a body of evidence, postulates that modern day cleanliness and sterile environments have promoted the development of allergic diseases, such as asthma, by reducing the exposure of individuals to non-infectious organisms during childhood (172–176). Accumulating evidence indicates that there is a timely window of opportunity during early life wherein disruptions in microbial colonization can increase the risk of asthma development in later life. Indeed, Bisgaard et al. reported that children who were colonized within 1 month of life by potentially pathogenic bacteria, including *H. influenzae* and *Mcat* were more likely to develop asthma by the age of 5 (165). Building on this seminal work, further analysis found associations between microbiome stability and respiratory health in the first 2 years of life (169). More stable microbiota profiles were dominated by *Moraxella* and were associated with a lower

number of consecutive respiratory infections (169). In contrast, other studies have found *Moraxella*-dominant microbiomes were associated with younger age of first upper RTI (177), increased number of RTIs (178), and increased severity of illness (177). The timing of *Moraxella* colonization appears to be crucial. In line with the original findings of Bosch et al., *Moraxella* becomes the dominant microbiome community member in healthy children much later (2–3 months) (178). Premature microbiome maturation involving an early transition to a *Moraxella*-dominant microbiome profile is associated with an increased number of RTIs (178).

Conversely, *Haemophilus*-dominated microbiome profiles are less temporally stable (169, 177), and emerge later than *Moraxella* (178). Characterization of the nasopharyngeal microbiome in the first 5 years of life found that the presence of *Haemophilus* was associated with increased respiratory tract illness symptoms, both synergistically and independently of viral presence (RSV and RV), indicating a bacteria-dependent contribution to respiratory illness (179). Furthermore, *H. influenzae* colonization was more significant in an “infection and allergy prone” subgroup of children in a retrospective analysis investigating the relationship between bacterial colonization and respiratory illness in children between 6 months and 5 years of age (180). This study also found a significant association between *H. influenzae* and influenza infection, which was not observed for other respiratory bacteria. It is not clear whether *Haemophilus* associations with early life asthma development is a consequence of altered microbiome maturation and immune training prior to the establishment of a *Haemophilus*-dominant microbiome. Overall, the mechanistic influence of colonizing bacteria on host responses prior to and during viral infection is not well-understood, highlighting the need to also characterize the functional relevance of early life bacterial colonization on immune tone, rather than just drawing correlations between bacterial presence with respiratory health outcomes.

Nonetheless, evidence indicates that airway bacteria modulate host immune responses. Exaggerated responses were observed in PBMC isolated from children prior to asthma development in later life, including increased IL-5, IL-13, IL-17, and IL-10 when exposed to *H. influenzae* and Mcat (181). Building on these observations, murine models of airway disease demonstrate a potential functional consequence of airway colonization by potentially pathogenic bacteria. Mice colonized with NTHi after only 3 days of life exhibited an exacerbated response when later challenged with an allergen, implicating NTHi in aberrant host immune development (182). Similarly, Mcat and allergen exposure synergistically resulted in an IL-17-mediated exacerbated immune response in mice (183). Development of aberrant host immune responses following early life colonization by bacteria may influence host responses to infections and contribute to asthma development. For example, mucosal-associated invariant T (MAIT) cells are important antibacterial innate-like immune cells which depend on microbiota-derived signals for timely development and maturation (184, 185). Thus, as a healthy microbiome appears to be crucial for MAIT cell-mediated resistance to infection, dysbiosis of the airway microbiome by pathogens such as NTHi and Mcat in early life

may influence MAIT cell development. Indeed, MAIT cells are activated upon NTHi infection of macrophages *in vitro* (186) and are important for host resistance to other respiratory pathogens (187, 188). Thus, dysregulation of MAIT cell function may contribute to aberrant immune responses in asthma.

As evidence indicates that these bacteria also chronically colonize the airway of individuals with established asthma, we will next explore how these bacteria can contribute to the development and persistence of asthma inflammatory phenotypes and modulate airway immune responses.

ESTABLISHED ASTHMA: THE ROLE OF COLONIZING BACTERIA IN SHAPING HOST IMMUNE RESPONSES AND INFLAMMATORY PHENOTYPES

Host-Pathogen Crosstalk During Persistent Airway Colonization

Although the importance of lung microbiome composition differences between health and disease is becoming apparent, the complexities of host-microbiome interactions are only now beginning to be appreciated (189). Increasing evidence indicates that the gut microbiome modulates the host mucosal defense response. However, less is known about the role of the lung microbiome in regulating the host immune response (190). Human lung microbiome studies have mainly consisted of using metagenomics on large cohorts to identify the microbiome composition. Although metagenomics is a powerful tool, measuring the relative abundance of bacterial species does not necessarily correlate with the activity of the microbes present (191).

As such, studies are now beginning to correlate microbial activity with host gene expression. Using a combination of shotgun RNA sequencing for microbial identification and host differential gene expression analysis, Castro-Nallar et al., identified a specific host gene profile associated with the presence of Proteobacteria (192). Expanding on this work, Perez-Losada et al., used dual transcriptomic profiling to assess differences in the host and microbial functional properties of asthmatic children and healthy controls (193). They found differences in bacterial metabolism-associated genes between the metatranscriptomes of asthmatic and non-asthmatic individuals, with host *IL1A* expression associated with bacterial adhesion (193). Further metabolic differences in the asthmatic bronchial microbiome was observed by Durack et al., who found enrichment of bacterial short chain fatty acid (SCFA) and amino acid metabolism in atopic asthmatics (53). Interestingly, this study also found functional differences in the microbiome were associated with ICS responsiveness, suggesting members of the microbiome may influence treatment efficacy. Unfortunately, due to the experimental limitation of low bacterial biomass in the lung, the sample size was too small to perform meaningful comparisons between T2 low/high individuals. Nonetheless, such studies demonstrate the importance of using metatranscriptomic approaches to determine the functional impact of these altered microbiome profiles in the development and progression of

asthma and modulation of host immune responses during stable periods of disease.

NTHi and the Neutrophil Inflammatory Phenotype

Numerous studies have identified associations between Proteobacteria and some of the main clinical features of asthma including increased bronchial hyperresponsiveness (129) and airway inflammation (52, 129), such as a mixed T1/T2/T17 inflammatory response (16, 194). Expansion of Proteobacteria appears to be inversely correlated with eosinophil levels but is significantly associated with increased neutrophil levels (16, 45). In particular, NTHi is detectable during stable periods of disease and is associated with T2-low inflammation, increased neutrophils and steroid-resistance [Figure 4; (45, 49)]. Development of steroid-resistance in asthma has been linked to increased NLRP3, caspase-1, and IL-1 β responses to NTHi infection (50, 195). Experimental models trying to reconcile the observations of NTHi and neutrophilic inflammation in cohort studies have shown that suppression of IL-1 β -mediated responses prevented the development of the steroid-resistant features of asthma (50). However, it remains unclear whether NTHi contributes to the progression of severe, neutrophilic, steroid-resistant asthma, or if NTHi takes advantage of the chronically inflamed and damaged airway that is characteristic of severe asthma to colonize the lung.

To try and untangle the complex mechanisms underlying this question, murine studies have investigated the development of neutrophilic disease following NTHi colonization. NTHi infection of ovalbumin (OVA)-sensitized mice resulted in an influx of IL-17+ macrophages, neutrophils, and lymphocytes, with eosinophilic inflammation reduced (196). Despite an influx of immune cells, NTHi infection was sustained in mice with allergic airways disease compared to non-allergic mice (197). The combination of allergic airways disease and infection contributed to the emergence of a steroid-resistant neutrophilic phenotype, suggesting the synergy between prior host allergic sensitization and subsequent NTHi infection promotes disease development. However, the duration of these aforementioned murine studies may be too short to ascertain whether the neutrophilic phenotype persists or if the neutrophilic inflammation was a transient event with inflammatory resolution occurring after the chosen study endpoint. Yang et al., extended the experimental endpoint to 2 months using OVA-sensitized mice and repeated low dose infections with NTHi to model NTHi chronic colonization of the airway (198). As a consequence, by the 2-month (56 day) endpoint, the inflammatory profile switched from T2-associated eosinophilic inflammation to T17-associated neutrophilic inflammation, accompanied by Treg immunosuppression and impaired macrophage phagocytosis. Together, these murine studies suggest that the combination of allergic airways disease and NTHi infection drives the neutrophilic inflammation, with this inflammatory phenotype still present 2 months after the first NTHi exposure. Thus, minimizing the burden of chronic NTHi presence in asthma could reduce the development of

steroid-resistance and improve outcomes for patients requiring steroids to manage their symptoms.

CHANGING THE TRAJECTORY: STRATEGIES TO REDUCE THE BURDEN OF PATHOGENS IN THE AIRWAY

As patients with T2-low asthma tend to respond poorly to current therapies, identifying which components of T2-low inflammation to therapeutically target is of utmost importance. However, current therapies targeting these alternate pathways have not shown to be effective. The IL-17 family of cytokines is implicated in more severe and neutrophilic forms of asthma, but a clinical trial treating patients with brodalumab, a monoclonal antibody targeting IL-17RA, did not show any clinical benefits for patients (199). However, a subpopulation within the trial cohort did show a clinically meaningful change in bronchodilator reversibility. Similarly, as a number of clinical and experimental studies have implicated the inflammasome and IL-1 mediated responses in neutrophilic asthma and steroid-resistance (50, 195, 200, 201), the notion of therapeutically targeting IL-1 β has progressed to clinical trials (202). Although use of an IL-1 receptor agonist reduced IL-1 β , IL-6, and IL-8 sputum levels in healthy volunteers challenged with LPS (203), trial outcomes in chronic respiratory disease have not yet been conclusive.

Due to the multifaceted nature of asthma, it is likely that treatment will be more successful using a personalized medicine approach. To achieve this, we must first understand whether the measured inflammation is a cause of disease or is a consequence of other underlying pathology not yet understood. This is perhaps exemplified by trials targeting the neutrophil chemokine receptor CXCR2. Although CXCR2 antagonists reduced neutrophil levels in sputum and blood, they did not reduce exacerbations, improve lung function or asthma score. Furthermore, neutrophil levels were reversible and was reversible after treatment ceased (204, 205). Identifying the underlying mechanisms in asthma pathogenesis will likely uncover treatable traits to develop novel therapeutics or reveal stratification strategies using phenotypic traits or biomarkers to more effectively treat patients with currently available therapies using a more targeted approach.

As accumulating evidence links respiratory tract infections and asthma pathogenesis, reducing the burden and carriage of the implicated pathogens has been suggested as an alternate strategy. Here we discuss some potential alternate and novel therapeutic strategies.

Vaccination

The annual influenza vaccine is available for individuals with asthma; however, no vaccine is currently available for RSV, RV, Mcat, or NTHi. Promisingly, vaccine candidates for these pathogens using a variety of vaccine technologies are at various stages of development (206–209), but further clinical trials are needed to assess their efficacy in reducing exacerbations in chronic respiratory disease. Recently, mRNA vaccines have proposed as an alternative vaccine platform to conventional vaccines (210). The success of the SARS-CoV-2 mRNA vaccine

potentially signifies the beginning of a new era of vaccination technology, which may allow for development of vaccines against respiratory pathogens previously difficult to vaccinate against (211).

Other alternative vaccinology methods such as Trained Immunity-based Vaccines (TIBV) have also been proposed. These vaccines are composed of multiple microbial components aimed at generating broad responses and stimulation of trained immunity to promote immunotolerant responses to live pathogens (212). Generating protective immune responses is also the aim of bacterial lysate therapy. Roth et al. (213) found that treatment with bacterial lysate components (OM-85) inhibited RV infection of airway epithelial cells *in vitro*, through increased anti-viral activity and upregulation of proteins involved in antigen presentation. A study using a murine infection model has also shown beneficial effects of bacterial lysate treatment on RSV and influenza infection, with inhibition of infection suggested to occur through TLR signaling (214). Importantly, bacterial lysate therapy was shown to reduce exacerbation frequency in individuals with asthma (215).

Novel Antibiotics/Anti-Inflammatories

Although antibiotics are commonly used to treat respiratory infections, antibiotic treatment is non-specific and subsequently has global, detrimental effects on microbiome community structure. Antibiotic use in early childhood may predispose individuals to asthma development by increasing the abundance of bacterial species associated with asthma development (177, 216, 217). However, the AMAZES (Asthma and Macrolides: The Azithromycin Efficacy and Safety) trial identified that azithromycin treatment reduced *H. influenzae* load and exacerbation risk. This trial demonstrated that long term treatment of asthmatic individuals with the macrolide, azithromycin, reduced exacerbations (218), and *H. influenzae* load in the airway (219). This finding was consistent with an earlier study in children with bronchiectasis treated with azithromycin (220). However, both studies found increased carriage of antibiotic resistance genes, a concern given the current antimicrobial resistance crisis. As such, reducing *H. influenzae* load through macrolide therapy may prevent exacerbations and the development of steroid-resistance in later life, but antibiotic use in early life may cause more detrimental effects.

Macrolide antibiotics have immunomodulatory properties, as well as antibacterial, which could improve the ability of macrophages to respond to NTHi in the airway. Use of another macrolide antibiotic, clarithromycin, reduced IL-17 responses in a murine model of *H. influenzae*-induced severe, steroid-insensitive, neutrophilic allergic airways disease (221). One of the suggested immunomodulatory properties of macrolides is promotion of macrophage phagocytosis. Treatment of healthy primary human AM and THP-1 differentiated macrophages with two novel non-antibiotic macrolides *in vitro* resulted in increased phagocytosis of NTHi and apoptotic epithelial cells, decreased IL-1 β levels and inflammasome activation (222). However, as macrophage phagocytosis decreases with worsening disease severity (76), the mechanisms of impairment may differ between

disease states and phagocytosis may not be restored by macrolide treatment. Use of *ex vivo* models may better recapitulate the human lung environment when assessing treatment efficacy of novel therapeutics (223). Nonetheless, the benefit of reducing *Haemophilus* presence in the airway is clear, highlighting the importance of discovering alternative, non-antibiotic avenues of therapy which can enhance or restore immune cell function, minimize airway bacterial load, and reduce inflammation.

Restoring the Balance of Host Immunity

The soluble human lung proteins SP-A and SP-D have diverse roles against viral and bacterial pathogens, as well as modulating the immune system and could also be exploited as exogenous therapeutics to treat asthma exacerbations through these mechanisms (224–227). Recombinant versions of these proteins have been developed and could have therapeutic potential in treating asthma exacerbations (225, 228). A recombinant fragment of SP-D is currently been taken forward to a first-in-human trial to prevent neonatal chronic lung disease in preterm infants (224).

As mentioned previously, elevated levels of inflammasome and IL-1 responses have been detected in neutrophilic asthma, but have also been associated with NTHi (50). Associations between NTHi and IL-1 β are not limited to asthma (50, 51, 197), with higher levels of IL-1 β measured in BAL samples from NTHi+ COPD patients compared to NTHi- COPD patients (229), as well as increased neutrophils in the airways of COPD patients colonized with *H. influenzae* (230). As such, targeting the IL-1 β pathway in chronic respiratory disease could attenuate the chronic inflammation caused by persistent NTHi colonization. More work is required to determine whether upregulation of inflammasome responses and IL-1 β in chronic respiratory disease is NTHi-specific or pan-bacterial, as IL-1 pathway interventions may only benefit a subset of patients with airway inflammation associated with NTHi-mediated IL-1 pathway activation. Thus, future trials could benefit from stratifying patients based on NTHi presence, which could improve the efficacy of IL-1 therapies that so far have shown to be ineffective in asthma (231).

As anti-viral immunity is impaired in asthma, restoring this immunity may reduce the risk of infection-driven exacerbations. In particular, type I IFN responses, mediated by IFN- β has shown to be crucial in anti-viral immunity (232–234). A randomized controlled trial investigating the effect of inhaled IFN- β did not meet its primary endpoint of assessing asthma symptoms, but did find improvements in morning peak flow and enhanced innate immunity, specifically ISG expression (235). The INEXAS (A Study in Asthma Patients to Evaluate Efficacy, Safety, and Tolerability of 14 Days Once Daily Inhaled Interferon Beta-1a after the Onset of Symptoms of an Upper Respiratory Tract Infection for the Prevention of Severe Exacerbations) trial also found small improvements in morning peak flow following use of inhaled IFN- β , but again, the primary endpoint was not met and the impact of inhaled IFN- β on the rate of severe asthma exacerbations was unable to be assessed (236). In contrast, inhaled IFN- β therapy was found to increase the odds of improvement in clinical status as well as time to recovery for

hospitalized COVID-19 patients (237). Importantly, studying the dynamics of IFN responses found that timing of IFN- β dosing is key; prophylactic IFN- β treatment reduced influenza infection of macrophage and epithelial cells, whereas this was not observed if cells were treated with IFN- β after influenza infection (238). Thus, the timing of treatment initiation is crucial for disease outcomes in those with underlying dysregulated immune responses, which will undoubtedly guide the development of future clinical studies and treatment guidance for individuals suffering from viral-induced exacerbations.

Microbiome Modulation: A Feasible Alternative Therapeutic Approach?

The accumulating number of studies demonstrating the presence of potentially pathogenic bacteria preceding viral infection and influencing respiratory health and asthma development, indicate that perhaps targeting these bacteria may be an attractive alternative therapeutic approach. Conversely, the absence of commensal bacteria may contribute to impaired immune development and training (239, 240). As such, attention turns to determining whether promoting the restoration of respiratory tract commensal species may result in more favorable outcomes, as has been observed for probiotics and the gut microbiome (241).

The importance of the commensal bacteria members of the microbiome for development of efficient immune responses has been previously shown in murine models. Antibiotic-treated mice displayed altered immune responses to respiratory viral infection following depletion of commensal bacteria (239, 240). The importance of microbiome community structure for immune training and development in the airway during early life is also shown in germ-free mice, who develop an exaggerated response to allergen challenge in the absence of microbial colonization (242). Furthermore, specific lung bacteria were either protective or inductive of certain asthma features following inoculation of mice, highlighting the divergent immunostimulatory capacity of different bacteria (243). These murine studies demonstrate the importance of the microbiome community structure in shaping appropriate immune responses to both allergens and infection.

Identification of the bacteria important for immune training and stable respiratory health is crucial if modulation of the lung microbiome is to prove feasible. Bosch et al. found that certain children transitioned more quickly from a *Staphylococcus*-profile to a *Moraxella*-dominant profile, bypassing a *Corynebacterium/Dolosigranulum*-dominated profile. Prolonged presence of this latter profile was associated with fewer RTIs and timely maturation of the microbiome in healthy children (178). This is in agreement with an earlier study by Biesbroek et al., who similarly identified *Corynebacterium/Dolosigranulum* airway presence to be associated with decreased number of parental-reported upper RTIs (169). A potential mechanism was suggested following modeling work, which

inoculated infant mice intranasally with *Corynebacterium pseudodiphtheriticum*. Activation of TLR3-mediated antiviral immunity was detected, resulting in reduced lung RSV viral titers and reduced susceptibility to secondary bacterial infection (244). Importantly, non-viable *C. pseudodiphtheriticum* did not induce the same protective responses, indicating the importance of live *C. pseudodiphtheriticum* colonization for modulating host immune responses.

Human challenge models have also shown the beneficial, protective effects of colonizing commensal bacteria; inoculation of human volunteers with *Neisseria lactamica* reduced *N. meningitidis* carriage (245). It is clear that the presence or absence of certain microbial species and their functional microbial interactions influence disease susceptibility and trajectory and unbalance host immune responses. However, as a recent study by Thorsen et al. implicates potential commensal *Prevotella* with altered host responses and asthma development, it is important to first ascertain the pathogenic potential of microbes when considering therapeutically altering microbiome structure (246). Nonetheless, unraveling the complex interplay between infection, atopy, host immunity, and genetic factors in early life will provide novel insights and may allow advanced identification and stratification of individuals at risk of developing asthma, for example if they possess certain genetic risk factors and microbiome characteristics.

Although the role of bacteria in asthma is only now becoming appreciated, there are even fewer studies investigating the role of fungi and the mycobiome in health and disease (247). Recent inclusion of fungi in airway microbiome studies has revealed a distinct airway mycobiome which is altered in asthma (248). A role for fungi in early life asthma development has also been suggested by Stern et al., who found that sensitization to certain fungal species was associated with asthma in later life (249). A recent study has identified associations between *Moraxella* presence and asthma-associated fungi (250). Given the possibility for multiple microbiota-host and other environmental interactions to occur, future studies need to ensure that all potential contributing factors are accounted for in study design and conclusions, in order to develop effective therapeutics.

SUMMARY

Accumulating evidence indicates an important role of both bacteria and viruses in driving asthma pathogenesis. Although viruses have long been implicated in asthma development and exacerbations, the enrichment of certain bacteria in the airway appears to play a more prominent role in asthma pathogenesis than initially believed. The composition of the microbiome in early life is crucial for immune training and development, which is reflected by aberrant responses in later life. Omics technologies are beginning to reveal the extent of microbiome modulation of the host in the respiratory tract and understand how it influences host-bacteria-virus crosstalk and relates to disease severity and progression. Although current

and developing therapies aim to reduce neutrophil/eosinophil recruitment and activation in asthma, emerging evidence indicates that the microbiome may contribute to chronic and dysregulated airway inflammation. As such, microbiome modulation may instead be an attractive alternative for managing airway inflammation and host immunity. This approach may rebalance and retrain appropriate host immune responses to inflammatory triggers and subsequently reduce the risk of asthma development in those with genetic predispositions. Furthermore, it may reduce the risk of exacerbation and progression to more severe disease in those with asthma already established.

REFERENCES

- Jackson DJ, Sykes A, Mallia P, Johnston SL. Asthma exacerbations: origin, effect, and prevention. *J Allergy Clin Immunol.* (2011) 128:1165–74. doi: 10.1016/j.jaci.2011.10.024
- Global Initiative for Asthma. *Global Strategy For Asthma Management and Prevention* (2021). Available online at: www.ginasthma.org
- Pearce N, Pekkanen J, Beasley R. How much asthma is really attributable to atopy? *Thorax.* (1999) 54:268–72. doi: 10.1136/thx.54.3.268
- Ahmad Al Obaidi AH, Mohamed Al Samarai AG, Yahya Al Samarai AK, Al Janabi JM. The predictive value of IgE as biomarker in asthma. *J Asthma.* (2008) 45:654–63. doi: 10.1080/02770900802126958
- Kim HY, Dekruyff RH, Umetsu DT. The many paths to asthma: phenotype shaped by innate and adaptive immunity. *Nat Immunol.* (2010) 11:577–84. doi: 10.1038/ni.1892
- Pembrey L, Barreto ML, Douwes J, Cooper P, Henderson J, Mpairwe H, et al. Understanding asthma phenotypes: the World Asthma Phenotypes (WASP) international collaboration. *ERJ Open Res.* (2018) 4:00013–2018. doi: 10.1183/23120541.00013-2018
- Baos S, Calzada D, Cremades-Jimeno L, Sastre J, Picado C, Quiralte J, et al. Nonallergic asthma and its severity: biomarkers for its discrimination in peripheral samples. *Front Immunol.* (2018) 9:1416. doi: 10.3389/fimmu.2018.01416
- Ishmael FT. The inflammatory response in the pathogenesis of asthma. *J Am Osteopath Assoc.* (2011) 111:S11–7. doi: 10.7556/jaoa.2011.20014
- Deckers J, Branco Madeira F, Hammad H. Innate immune cells in asthma. *Trends Immunol.* (2013) 34:540–7. doi: 10.1016/j.it.2013.08.004
- Wadhwa R, Dua K, Adcock IM, Horvat JC, Kim RY, Hansbro PM. Cellular mechanisms underlying steroid-resistant asthma. *Eur Respir Rev.* (2019) 28:190096. doi: 10.1183/16000617.0096-2019
- Fahy JV. Type 2 inflammation in asthma—present in most, absent in many. *Nat Rev Immunol.* (2015) 15:57–65. doi: 10.1038/nri3786
- Douwes J, Gibson P, Pekkanen J, Pearce N. Non-eosinophilic asthma: importance and possible mechanisms. *Thorax.* (2002) 57:643–8. doi: 10.1136/thorax.57.7.643
- Kuo CHS, Pavlidis S, Loza M, Baribaud F, Rowe A, Pandis I, et al. T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED. *Eur Respir J.* (2017) 49:1602135. doi: 10.1183/13993003.02135-2016
- Ordoñez CL, Shaughnessy TE, Matthay MA, Fahy JV. Increased neutrophil numbers and IL-8 levels in airway secretions in acute severe asthma: clinical and biologic significance. *Am J Respir Crit Care Med.* (2000) 161:1185–90. doi: 10.1164/ajrccm.161.4.9812061
- Yang X, Li H, Ma Q, Zhang Q, Wang C. Neutrophilic asthma is associated with increased airway bacterial burden and disordered community composition. *Biomed Res Int.* (2018) 2018:1–11. doi: 10.1155/2018/9230234
- Huang YJ, Nariya S, Harris JM, Lynch SV, Choy DE, Arron JR, et al. The airway microbiome in patients with severe asthma: associations with disease features and severity. *J Allergy Clin Immunol.* (2015) 136:874–84. doi: 10.1016/j.jaci.2015.05.044

AUTHOR CONTRIBUTIONS

JA, KS, and TW conceptualized the review article. JA and KS wrote the original draft. JA performed the literature search. AW and TW reviewed and edited the manuscript. KS and TW supervised. All authors approved the final version of the manuscript.

FUNDING

This work was funded by an Asthma UK studentship award (AUK-PHD-2016-363).

- Moore WC, Hastie AT, Li X, Li H, Busse WW, Jarjour NN, et al. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. *J Allergy Clin Immunol.* (2014) 133:1557–63.e5. doi: 10.1016/j.jaci.2013.10.011
- Bosnjak B, Stelzmueller B, Erb KJ, Epstein MM. Treatment of allergic asthma: modulation of Th2 cells and their responses. *Respir Res.* (2011) 12:114. doi: 10.1186/1465-9921-12-114
- Reddel H, Ware S, Marks G, Salome C, Jenkins C, Woolcock A. Differences between asthma exacerbations and poor asthma control. *Lancet.* (1999) 353:364–9. doi: 10.1016/S0140-6736(98)06128-5
- Sears MR. Epidemiology of asthma exacerbations. *J Allergy Clin Immunol.* (2008) 122:662–8. doi: 10.1016/j.jaci.2008.08.003
- Wark PAB, Gibson PG. Asthma exacerbations. 3: pathogenesis. *Thorax.* (2006) 61:909–15. doi: 10.1136/thx.2005.045187
- Bloom CL, Nissen F, Douglas IJ, Smeeth L, Cullinan P, Quint JK. Exacerbation risk and characterisation of the UK's asthma population from infants to old age. *Thorax.* (2018) 73:313–20. doi: 10.1136/thoraxjnl-2017-210650
- Bai TR, Vonk JM, Postma DS, Boezen HM. Severe exacerbations predict excess lung function decline in asthma. *Eur Respir J.* (2007) 30:452–6. doi: 10.1183/09031936.00165106
- Ortega H, Yancey SW, Keene ON, Gunsoy NB, Albers FC, Howarth PH. Asthma exacerbations associated with lung function decline in patients with severe eosinophilic asthma. *J Allergy Clin Immunol Pract.* (2018) 6:980–6.e1. doi: 10.1016/j.jaip.2017.12.019
- O'Byrne PM, Pedersen S, Lamm CJ, Tan WC, Busse WW. Severe exacerbations and decline in lung function in asthma. *Am J Respir Crit Care Med.* (2009) 179:19–24. doi: 10.1164/rccm.200807-1126OC
- Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. *Nat Med.* (2012) 18:716–25. doi: 10.1038/nm.2678
- O'Byrne PM. Role of monoclonal antibodies in the treatment of asthma. *Can Respir J.* (2013) 20:23–5. doi: 10.1155/2013/183948
- Garcia G, Taillé C, Laveneziana P, Bourdin A, Chanez P, Humbert M. Anti-interleukin-5 therapy in severe asthma. *Eur Respir Rev.* (2013) 22:251–7. doi: 10.1183/09059180.00004013
- Poznanski SM, Mukherjee M, Zhao N, Huang C, Radford K, Ashkar AA, et al. Asthma exacerbations on benralizumab are largely non-eosinophilic. *Allergy.* (2021) 76:375–9. doi: 10.1111/all.14514
- Edwards MR, Saglani S, Schwarze J, Skevaki C, Smith JA, Ainsworth B, et al. Addressing unmet needs in understanding asthma mechanisms: from the European Asthma Research and Innovation Partnership (EARIP) Work Package (WP) 2 collaborators. *Eur Respir J.* (2017) 49:1602448. doi: 10.1183/13993003.02448-2016
- Baldacci S, Maio S, Cerrai S, Sarno G, Baiz N, Simoni M, et al. Allergy and asthma: effects of the exposure to particulate matter and biological allergens. *Respir Med.* (2015) 109:1089–104. doi: 10.1016/j.rmed.2015.05.017
- Cecchi L, D'Amato G, Annesi-Maesano I. External exposome and allergic respiratory and skin diseases. *J Allergy Clin Immunol.* (2018) 141:846–57. doi: 10.1016/j.jaci.2018.01.016
- Bisgaard H, Hermansen MN, Bonnelykke K, Stokholm J, Batty F, Skjott NL, et al. Association of bacteria and viruses with wheezy

- episodes in young children: prospective birth cohort study. *BMJ*. (2010)341:770. doi: 10.1136/bmj.c4978
34. Wark PAB, Toozé M, Powell H, Parsons K. Viral and bacterial infection in acute asthma and chronic obstructive pulmonary disease increases the risk of readmission. *Respirology*. (2013) 18:996–1002. doi: 10.1111/resp.12099
 35. Minor TE, Dick EC, DeMeo AN, Ouellette JJ, Cohen M, Reed CE. Viruses as precipitants of asthmatic attacks in children. *JAMA*. (1974) 227:292–8. doi: 10.1001/jama.1974.03230160020004
 36. Lemanske RF, Dick EC, Swenson CA, Vrtis RF, Busse WW. Rhinovirus upper respiratory infection increases airway hyperreactivity and late asthmatic reactions. *J Clin Invest*. (1989) 83:1–10. doi: 10.1172/JCI113843
 37. Bardin PG, Fraenkel DJ, Sanderson G, Dorward M, Lau LCK, Johnston SL, et al. Amplified rhinovirus colds in atopic subjects. *Clin Exp Allergy*. (1994) 24:457–64. doi: 10.1111/j.1365-2222.1994.tb00934.x
 38. Papadopoulos NG, Christodoulou I, Rohde G, Agache I, Almqvist C, Bruno A, et al. Viruses and bacteria in acute asthma exacerbations - a GA²LEN-DARE systematic review. *Allergy*. (2011) 66:458–68. doi: 10.1111/j.1398-9995.2010.02505.x
 39. Denlinger LC, Sorkness RL, Lee WM, Evans MD, Wolff MJ, Mathur SK, et al. Lower airway rhinovirus burden and the seasonal risk of asthma exacerbation. *Am J Respir Crit Care Med*. (2011) 184:1007–14. doi: 10.1164/rccm.201103-0585OC
 40. Fleming HE, Little FF, Schnurr D, Avila PC, Wong H, Liu J, et al. Rhinovirus-16 colds in healthy and in asthmatic subjects: similar changes in upper and lower airways. *Am J Respir Crit Care Med*. (1999) 160:100–8. doi: 10.1164/ajrccm.160.1.9808074
 41. DeMore JP, Weishaar EH, Vrtis RF, Swenson CA, Evans MD, Morin A, et al. Similar colds in subjects with allergic asthma and nonatopic subjects after inoculation with rhinovirus-16. *J Allergy Clin Immunol*. (2009) 124:245–52, 252.e1–3. doi: 10.1016/j.jaci.2009.05.030
 42. Lamson D, Renwick N, Kapoor V, Liu Z, Palacios G, Ju J, et al. MassTag polymerase-chain-reaction detection of respiratory pathogens, including a new rhinovirus genotype, that caused influenza-like illness in New York State during 2004–2005. *J Infect Dis*. (2006) 194:1398–402. doi: 10.1086/508551
 43. Bizzintino J, Lee WM, Laing IA, Vang F, Pappas T, Zhang G, et al. Association between human rhinovirus C and severity of acute asthma in children. *Eur Respir J*. (2011) 37:1037–42. doi: 10.1183/09031936.00092410
 44. Sutherland ER, Martin RJ. Asthma and atypical bacterial infection. *Chest*. (2007) 132:1962–6. doi: 10.1378/chest.06-2415
 45. Green BJ, Wiriyachaiorn S, Grainge C, Rogers GB, Kehagia V, Lau R, et al. Potentially pathogenic airway bacteria and neutrophilic inflammation in treatment resistant severe asthma. *PLoS ONE*. (2014) 9:e100645. doi: 10.1371/journal.pone.0100645
 46. Iikura M, Hojo M, Koketsu R, Watanabe S, Sato A, Chino H, et al. The importance of bacterial and viral infections associated with adult asthma exacerbations in clinical practice. *PLoS ONE*. (2015) 10:e0123584. doi: 10.1371/journal.pone.0123584
 47. Zhang Q, Cox M, Liang Z, Brinkmann F, Cardenas PA, Duff R, et al. Airway microbiota in severe asthma and relationship to asthma severity and phenotypes. *PLoS ONE*. (2016) 11:e0152724. doi: 10.1371/journal.pone.0152724
 48. Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C, et al. Disordered microbial communities in asthmatic airways. *PLoS ONE*. (2010) 5:e8578. doi: 10.1371/journal.pone.0008578
 49. Simpson JL, Daly J, Baines KJ, Yang IA, Upham JW, Reynolds PN, et al. Airway dysbiosis: *Haemophilus influenzae* and tropheryma in poorly controlled asthma. *Eur Respir J*. (2016) 47:792–800. doi: 10.1183/13993003.00405-2015
 50. Kim RY, Pinkerton JW, Essilfie AT, Robertson AAB, Baines KJ, Brown AC, et al. Role for NLRP3 inflammasome-mediated, IL-1 β -dependent responses in severe, steroid-resistant asthma. *Am J Respir Crit Care Med*. (2017) 196:283–97. doi: 10.1164/rccm.201609-1830OC
 51. Taylor SL, Leong LEX, Choo JM, Wesselingh S, Yang IA, Upham JW, et al. Inflammatory phenotypes in patients with severe asthma are associated with distinct airway microbiology. *J Allergy Clin Immunol*. (2018) 141:94–103.e15. doi: 10.1016/j.jaci.2017.03.044
 52. Wood LG, Simpson JL, Hansbro PM, Gibson PG. Potentially pathogenic bacteria cultured from the sputum of stable asthmatics are associated with increased 8-isoprostane and airway neutrophilia. *Free Radic Res*. (2010) 44:146–54. doi: 10.3109/10715760903362576
 53. Durack J, Lynch SV, Nariya S, Bhakta NR, Beigelman A, Castro M, et al. Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment. *J Allergy Clin Immunol*. (2017) 140:63–75. doi: 10.1016/j.jaci.2016.08.055
 54. Zhou Y, Jackson D, Bacharier LB, Mauger D, Boushey H, Castro M, et al. The upper-airway microbiota and loss of asthma control among asthmatic children. *Nat Commun*. (2019) 10:5714. doi: 10.1038/s41467-019-13698-x
 55. McCauley K, Durack J, Valladares R, Fadrosch DW, Lin DL, Calatroni A, et al. Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma. *J Allergy Clin Immunol*. (2019) 144:1187–97. doi: 10.1016/j.jaci.2019.05.035
 56. Xatzipsalti M, Psaros F, Konstantinou G, Gaga M, Gourgiotis D, Saxonipapageorgiou P, et al. Modulation of the epithelial inflammatory response to rhinovirus in an atopic environment. *Clin Exp Allergy*. (2008) 38:466–72. doi: 10.1111/j.1365-2222.2007.02906.x
 57. Tiwary M, Rooney RJ, Liedmann S, LeMessurier KS, Samarasinghe AE. Eosinophil responses at the airway epithelial barrier during the early phase of influenza A virus infection in C57BL/6 mice. *Cells*. (2021) 10:509. doi: 10.3390/cells10030509
 58. Samarasinghe AE, Woolard SN, Boyd KL, Hoselton SA, Schuh JM, McCullers JA. The immune profile associated with acute allergic asthma accelerates clearance of influenza virus. *Immunol Cell Biol*. (2014) 92:449. doi: 10.1038/icb.2013.113
 59. Green RM, Custovic A, Sanderson G, Hunter J, Johnston SL, Woodcock A. Synergism between allergens and viruses and risk of hospital admission with asthma: case-control study. *Br Med J*. (2002) 324:763–6. doi: 10.1136/bmj.324.7340.763
 60. Calhoun WJ, Dick EC, Schwartz LB, Busse WW. A common cold virus, rhinovirus 16, potentiates airway inflammation after segmental antigen bronchoprovocation in allergic subjects. *J Clin Invest*. (1994) 94:2200–8. doi: 10.1172/JCI117581
 61. Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, et al. Randomized trial of omalizumab (Anti-IgE) for asthma in inner-city children. *N Engl J Med*. (2011) 364:1005–15. doi: 10.1056/NEJMoa1009705
 62. Wark PAB, Grissell T, Davies B, See H, Gibson PG. Diversity in the bronchial epithelial cell response to infection with different rhinovirus strains. *Respirology*. (2009) 14:180–6. doi: 10.1111/j.1440-1843.2009.01480.x
 63. Lee SMY, Gardy JL, Cheung CY, Cheung TKW, Hui KPY, Ip NY, et al. Systems-level comparison of host-responses elicited by avian H5N1 and seasonal H1N1 influenza viruses in primary human macrophages. *PLoS ONE*. (2009) 4:e8072. doi: 10.1371/journal.pone.0008072
 64. Friesenhagen J, Boergeling Y, Hrinčius E, Ludwig S, Roth J, Viemann D. Highly pathogenic avian influenza viruses inhibit effective immune responses of human blood-derived macrophages. *J Leukoc Biol*. (2012) 92:11–20. doi: 10.1189/jlb.0911479
 65. Hewson CA, Haas JJ, Bartlett NW, Message SD, Laza-Stanca V, Kebabdzé T, et al. Rhinovirus induces MUC5AC in a human infection model and *in vitro* via NF- κ B and EGFR pathways. *Eur Respir J*. (2010) 36:1425–35. doi: 10.1183/09031936.00026910
 66. Thomas B, Rutman A, Hirst RA, Haldar P, Wardlaw AJ, Bankart J, et al. Ciliary dysfunction and ultrastructural abnormalities are features of severe asthma. *J Allergy Clin Immunol*. (2010) 126:722–9.e2. doi: 10.1016/j.jaci.2010.05.046
 67. Tristram DA, Hicks W, Hard R. Respiratory syncytial virus and human bronchial epithelium. *Arch Otolaryngol Head Neck Surg*. (1998) 124:777–83. doi: 10.1001/archotol.124.7.777
 68. Rogers DF. Airway mucus hypersecretion in asthma: an undervalued pathology? *Curr Opin Pharmacol*. (2004) 4:241–50. doi: 10.1016/j.coph.2004.01.011
 69. Ordoñez CL, Khashayar R, Wong HH, Ferrando R, Wu R, Hyde DM, et al. Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression. *Am J Respir Crit Care Med*. (2001) 163:517–23. doi: 10.1164/ajrccm.163.2.2004039
 70. Aikawa T, Shimura S, Sasaki H, Ebina M, Takishima T. Marked goblet cell hyperplasia with mucus accumulation in the airways of

- patients who died of severe acute asthma attack. *Chest*. (1992) 101:916–21. doi: 10.1378/chest.101.4.916
71. Heymann PW, Nguyen HT, Steinke JW, Turner RB, Woodfolk JA, Platts-Mills TAE, et al. Rhinovirus infection results in stronger and more persistent genomic dysregulation: evidence for altered innate immune response in asthmatics at baseline, early in infection, and during convalescence. *PLoS ONE*. (2017) 12:e0178096. doi: 10.1371/journal.pone.0178096
 72. Wark PAB, Johnston SL, Bucchieri F, Powell R, Puddicombe S, Laza-Stanca V, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. *J Exp Med*. (2005) 201:937–47. doi: 10.1084/jem.20041901
 73. Sykes A, Edwards MR, MacIntyre J, Del Rosario A, Bakhsoliani E, Trujillo-Torralbo MB, et al. Rhinovirus 16-induced IFN- α and IFN- β are deficient in bronchoalveolar lavage cells in asthmatic patients. *J Allergy Clin Immunol*. (2012) 129:1506–14.e6. doi: 10.1016/j.jaci.2012.03.044
 74. Mackay RMA, Grainge CL, Lau LC, Barber C, Clark HW, Howarth PH. Airway surfactant protein D deficiency in adults with severe asthma. *Chest*. (2016) 149:1165–72. doi: 10.1016/j.chest.2015.11.012
 75. Staples KJ, Hinks TSC, Ward JA, Gunn V, Smith C, Djukanović R. Phenotypic characterization of lung macrophages in asthmatic patients: overexpression of CCL17. *J Allergy Clin Immunol*. (2012) 130:1404–12.e7. doi: 10.1016/j.jaci.2012.07.023
 76. Liang Z, Zhang Q, Thomas CMR, Chana KK, Gibeon D, Barnes PJ, et al. Impaired macrophage phagocytosis of bacteria in severe asthma. *Respir Res*. (2014) 15:72. doi: 10.1186/1465-9921-15-72
 77. Huynh MLN, Malcolm KC, Kotaru C, Tilstra JA, Westcott JY, Fadok VA, et al. Defective apoptotic cell phagocytosis attenuates prostaglandin E 2 and 15-hydroxyicosatetraenoic acid in severe asthma alveolar macrophages. *Am J Respir Crit Care Med*. (2005) 172:972–9. doi: 10.1164/rccm.200501-035OC
 78. Klopfer KM, Lee WM, Pappas TE, Kang TJ, Vrtis RF, Evans MD, et al. Detection of pathogenic bacteria during rhinovirus infection is associated with increased respiratory symptoms and asthma exacerbations. *J Allergy Clin Immunol*. (2014) 133:1301–7.e3. doi: 10.1016/j.jaci.2014.02.030
 79. Bashir H, Grindle K, Vrtis R, Vang F, Kang T, Salazar L, et al. Association of rhinovirus species with common cold and asthma symptoms and bacterial pathogens. *J Allergy Clin Immunol*. (2018) 141:822–4.e9. doi: 10.1016/j.jaci.2017.09.027
 80. Yoshii Y, Shimizu K, Morozumi M, Chiba N, Ubukata K, Uruga H, et al. Detection of pathogens by real-time PCR in adult patients with acute exacerbation of bronchial asthma. *BMC Pulm Med*. (2017) 17:150. doi: 10.1186/s12890-017-0494-3
 81. Blyth CC, Webb SAR, Kok J, Dwyer DE, van Hal SJ, Foo H, et al. The impact of bacterial and viral co-infection in severe influenza. *Influenza Other Respiri Viruses*. (2013) 7:168–76. doi: 10.1111/irv.12398
 82. Klein EY, Monteforte B, Gupta A, Jiang W, May L, Hsieh YH, et al. The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. *Influenza Other Respiri Viruses*. (2016) 10:394–403. doi: 10.1111/irv.12398
 83. Dao CN, Kamimoto L, Nowell M, Reingold A, Gershman K, Meek J, et al. Adult hospitalizations for laboratory-positive influenza during the 2005–2006 through 2007–2008 seasons in the United States. *J Infect Dis*. (2010) 202:881–8. doi: 10.1086/655904
 84. Wilkinson TMA, Hurst JR, Perera WR, Wilks M, Donaldson GC, Wedzicha JA. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. *Chest*. (2006) 129:317–24. doi: 10.1378/chest.129.2.317
 85. Wilkinson TMA, Aris E, Bourne S, Clarke SC, Peeters M, Pascal TG, et al. A prospective, observational cohort study of the seasonal dynamics of airway pathogens in the aetiology of exacerbations in COPD. *Thorax*. (2017) 72:919–27. doi: 10.1136/thoraxjnl-2016-209023
 86. Avadhanula V, Rodriguez CA, DeVincenzo JB, Wang Y, Webby RJ, Ulett GC, et al. Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species- and cell type-dependent manner. *J Virol*. (2006) 80:1629–36. doi: 10.1128/JVI.80.4.1629-1636.2006
 87. Frick AG, Joseph TD, Pang L, Rabe AM, St. Geme JW, Look DC. *Haemophilus influenzae* stimulates ICAM-1 expression on respiratory epithelial cells. *J Immunol*. (2000) 164:4185–96. doi: 10.4049/jimmunol.164.8.4185
 88. Xie H, Gu XX. *Moraxella catarrhalis* lipooligosaccharide selectively upregulates ICAM-1 expression on human monocytes and stimulates adjacent naive monocytes to produce TNF- α through cellular cross-talk. *Cell Microbiol*. (2008) 10:1453–67. doi: 10.1111/j.1462-5822.2008.01138.x
 89. Avadhanula V, Rodriguez CA, Ulett GC, Bakaletz LO, Adderson EE. Nontypeable *Haemophilus influenzae* adheres to intercellular adhesion molecule 1 (ICAM-1) on respiratory epithelial cells and upregulates ICAM-1 expression. *Infect Immun*. (2006) 74:830–8. doi: 10.1128/IAI.74.2.830-838.2006
 90. Gulraiz F, Bellinghausen C, Bruggeman CA, Stassen FR. *Haemophilus influenzae* increases the susceptibility and inflammatory response of airway epithelial cells to viral infections. *FASEB J*. (2015) 29:849–58. doi: 10.1096/fj.14-254359
 91. Edinger TO, Pohl MO, Stertz S. Entry of influenza A virus: host factors and antiviral targets. *J Gen Virol*. (2014) 95:263–77. doi: 10.1099/vir.0.059477-0
 92. St Geme JW, Falkow S, Barenkamp SJ. High-molecular-weight proteins of nontypeable *Haemophilus influenzae* mediate attachment to human epithelial cells. *Proc Natl Acad Sci USA*. (1993) 90:2875–9. doi: 10.1073/pnas.90.7.2875
 93. Ng PSK, Day CJ, Attack JM, Hartley-Tassell LE, Winter LE, Marshanski T, et al. Nontypeable *Haemophilus influenzae* has evolved preferential use of N-acetylneuraminic acid as a host adaptation. *MBio*. (2019) 10:e00422–19. doi: 10.1128/mBio.00422-19
 94. Heise T, Langeris JD, Rossing E, de Jonge MI, Adema GJ, Büll C, et al. Selective inhibition of sialic acid-based molecular mimicry in *Haemophilus influenzae* abrogates serum resistance. *Cell Chem Biol*. (2018) 25:1279–85.e8. doi: 10.1016/j.chembiol.2018.05.018
 95. Attack JM, Day CJ, Poole J, Brockman KL, Timms JRL, Winter LE, et al. The nontypeable *Haemophilus influenzae* major adhesin hia is a dual-function lectin that binds to human-specific respiratory tract sialic acid glycan receptors. *MBio*. (2020) 11:e02714–20. doi: 10.1128/mBio.02714-20
 96. St. Geme JW. The HMW1 adhesin of nontypeable *Haemophilus influenzae* recognizes sialylated glycoprotein receptors on cultured human epithelial cells. *Infect Immun*. (1994) 62:3881–9. doi: 10.1128/iai.62.9.3881-3889.1994
 97. Damasio GAC, Pereira LA, Moreira SDR, Duarte dos Santos CN, Dalla-Costa LM, Raboni SM. Does virus-bacteria coinfection increase the clinical severity of acute respiratory infection? *J Med Virol*. (2015) 87:1456–61. doi: 10.1002/jmv.24210
 98. Nita-Lazar M, Banerjee A, Feng C, Amin MN, Frieman MB, Chen WH, et al. Desialylation of airway epithelial cells during influenza virus infection enhances pneumococcal adhesion via galectin binding. *Mol Immunol*. (2015) 65:1–16. doi: 10.1016/j.molimm.2014.12.010
 99. Cooper GE, Pounce ZC, Wallington JC, Bastidas-Legarda LY, Nicholas B, Chidomere C, et al. Viral inhibition of bacterial phagocytosis by human macrophages: redundant role of CD36. *PLoS ONE*. (2016) 11:e0163889. doi: 10.1371/journal.pone.0163889
 100. Roquilly A, Jacqueline C, Davieau M, Mollé A, Sadek A, Fourgeux C, et al. Alveolar macrophages are epigenetically altered after inflammation, leading to long-term lung immunoparalysis. *Nat Immunol*. (2020) 21:636–48. doi: 10.1038/s41590-020-0673-x
 101. Didierlaurent A, Goulding J, Patel S, Snelgrove R, Low L, Bebie M, et al. Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. *J Exp Med*. (2008) 205:323–9. doi: 10.1084/jem.20070891
 102. Ghoneim HE, Thomas PG, McCullers JA. Depletion of alveolar macrophages during influenza infection facilitates bacterial superinfections. *J Immunol*. (2013) 191:1250–9. doi: 10.4049/jimmunol.1300014
 103. Oliver BGG, Lim S, Wark P, Laza-Stanca V, King N, Black JL, et al. Rhinovirus exposure impairs immune responses to bacterial products in human alveolar macrophages. *Thorax*. (2008) 63:519–25. doi: 10.1136/thx.2007.081752
 104. Maciejewski BA, Jamieson KC, Arnason JW, Kooi C, Wiehler S, Traves SL, et al. Rhinovirus-bacteria coexposure synergistically induces CCL20 production from human bronchial epithelial cells. *Am J Physiol Lung Cell Mol Physiol*. (2017) 312:L731–40. doi: 10.1152/ajplung.00362.2016
 105. Wu X, Li R, Weng Y, Zhou H, Jiang H, Zhao J, et al. Correlation of adhesion molecules and non-typeable *Haemophilus influenzae* growth in a mice coinfecting model of acute inflammation. *Microbes Infect*. (2021) 104839. doi: 10.1016/j.micinf.2021.104839. [Epub ahead of print].

106. LeMessurier KS, Iverson AR, Chang TC, Palipane M, Vogel P, Rosch JW, et al. Allergic inflammation alters the lung microbiome and hinders synergistic co-infection with H1N1 influenza virus and *Streptococcus pneumoniae* in C57BL/6 mice. *Sci Rep.* (2019) 9:19360. doi: 10.1038/s41598-019-55712-8
107. Morey P, Cano V, Martí-Lliteras P, López-Gómez A, Regueiro V, Saus C, et al. Evidence for a non-replicative intracellular stage of nontypeable *Haemophilus influenzae* in epithelial cells. *Microbiology.* (2011) 157:234–50. doi: 10.1099/mic.0.040451-0
108. Ahrén IL, Williams DL, Rice PJ, Forsgren A, Riesbeck K. The importance of a β -glucan receptor in the nonopsonic entry of nontypeable *Haemophilus influenzae* into human monocytic and epithelial cells. *J Infect Dis.* (2001) 184:150–8. doi: 10.1086/322016
109. Craig JE, Cliffe A, Garnett K, High NJ. Survival of nontypeable *Haemophilus influenzae* in macrophages. *FEMS Microbiol Lett.* (2001) 203:55–61. doi: 10.1111/j.1574-6968.2001.tb10820.x
110. Craig JE, Nobbs A, High NJ. The extracytoplasmic sigma factor, σE , is required for intracellular survival of nontypeable *Haemophilus influenzae* in J774 macrophages. *Infect Immun.* (2002) 70:708–15. doi: 10.1128/IAI.70.2.708-715.2002
111. King P, Ngui J, Oppedisano F, Robins-Browne R, Holmes P, Holdsworth S. Effect of interferon gamma and CD40 ligation on intracellular monocyte survival of nontypeable *Haemophilus influenzae*. *APMIS.* (2008) 116:1043–9. doi: 10.1111/j.1600-0463.2008.01078.x
112. Hutton AJ, Polak ME, Spalluto CM, Wallington JC, Pickard C, Staples KJ, et al. Human lung fibroblasts present bacterial antigens to autologous lung Th cells. *J Immunol.* (2017) 198:110–8. doi: 10.4049/jimmunol.1600602
113. Slevogt H, Seybold J, Tiwari KN, Hocke AC, Jonat C, Dietel S, et al. *Moraxella catarrhalis* is internalized in respiratory epithelial cells by a trigger-like mechanism and initiates a TLR2- and partly NOD1-dependent inflammatory immune response. *Cell Microbiol.* (2007) 9:694–707. doi: 10.1111/j.1462-5822.2006.00821.x
114. Spaniol V, Heiniger N, Troller R, Aebi C. Outer membrane protein UspA1 and lipooligosaccharide are involved in invasion of human epithelial cells by *Moraxella catarrhalis*. *Microbes Infect.* (2008) 10:3–11. doi: 10.1016/j.micinf.2007.09.014
115. Heiniger N, Spaniol V, Troller R, Vischer M, Aebi C. A reservoir of *Moraxella catarrhalis* in human pharyngeal lymphoid tissue. *J Infect Dis.* (2007) 196:1080–7. doi: 10.1086/521194
116. Gallo MC, Kirkham C, Eng S, Bebaewee RS, Kong Y, Pettigrew MM, et al. Changes in IgA protease expression are conferred by changes in genomes during persistent infection by nontypeable *Haemophilus influenzae* in chronic obstructive pulmonary disease. *Infect Immun.* (2018) 86:e00313–18. doi: 10.1128/IAI.00313-18
117. Pettigrew MM, Ahearn CP, Gent JE, Kong Y, Gallo MC, Munro JB, et al. *Haemophilus influenzae* genome evolution during persistence in the human airways in chronic obstructive pulmonary disease. *Proc Natl Acad Sci USA.* (2018) 115:E3256–65. doi: 10.1073/pnas.1719654115
118. Murphy TF, Brauer AL, Schiffmacher AT, Sethi S. Persistent colonization by *Haemophilus influenzae* in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* (2004) 170:266–72. doi: 10.1164/rccm.200403-354OC
119. Yano H, Suetake M, Kuga A, Irinoda K, Okamoto R, Kobayashi T, et al. Pulsed-field gel electrophoresis analysis of nasopharyngeal flora in children attending a day care center. *J Clin Microbiol.* (2000) 38:625–9. doi: 10.1128/JCM.38.2.625-629.2000
120. Heinrich A, Haarmann H, Zahradnik S, Frenzel K, Schreiber F, Klassert TE, et al. *Moraxella catarrhalis* decreases antiviral innate immune responses by down-regulation of TLR3 via inhibition of p53 in human bronchial epithelial cells. *FASEB J.* (2016) 30:2426–34. doi: 10.1096/fj.201500172R
121. Sajjan US, Jia Y, Newcomb DC, Bentley JK, Lukacs NW, LiPuma JJ, et al. *H. influenzae* potentiates airway epithelial cell responses to rhinovirus by increasing ICAM-1 and TLR3 expression. *FASEB J.* (2006) 20:2121–3. doi: 10.1096/fj.06-5806fj
122. Sakai A, Koga T, Lim JH, Jono H, Harada K, Szymanski E, et al. The bacterium, nontypeable *Haemophilus influenzae*, enhances host antiviral response by inducing Toll-like receptor 7 expression: evidence for negative regulation of host antiviral response by CYLD. *FEBS J.* (2007) 365:5–68. doi: 10.1111/j.1742-4658.2007.05899.x
123. Rupani H, Martinez-Nunez RT, Dennison P, Lau LCK, Jayasekera N, Havelock T, et al. Toll-like receptor 7 is reduced in severe asthma and linked to an altered MicroRNA profile. *Am J Respir Crit Care Med.* (2016) 194:26–37. doi: 10.1164/rccm.201502-0280OC
124. Habibi MS, Thwaites RS, Chang M, Jozwik A, Paras A, Kirsebom F, et al. Neutrophilic inflammation in the respiratory mucosa predisposes to RSV infection. *Science.* (2020) 370:eaba9301. doi: 10.1126/science.aba9301
125. De Steenhuijsen P, WAA, Heinonen S, Hasrat R, Bunsow E, Smith B, Suarez-Arrabal MC, et al. Nasopharyngeal microbiota, host transcriptome, and disease severity in children with respiratory syncytial virus infection. *Am J Respir Crit Care Med.* (2016) 194:1104–15. doi: 10.1164/rccm.201602-0220OC
126. Barber C, Ward J, Elliott S, Lau L, Azim A, Gove K, et al. Comparison of two published definitions of sputum neutrophilia show clinical measures of disease are more severe in neutrophilic asthma (NA) than non-neutrophilic asthma (NNA) using >40% sputum neutrophils as the definition of disease. *Eur Respir J.* (2020) 56:1255. doi: 10.1183/13993003.congress-2020.1255
127. Arron JR, Choy DF, Laviolette M, Kelsen SG, Hatab A, Leigh R, et al. Disconnect between sputum neutrophils and other measures of airway inflammation in asthma. *Eur Respir J.* (2014) 43:627–9. doi: 10.1183/09031936.00117013
128. Goleva E, Jackson LP, Harris JK, Robertson CE, Sutherland ER, Hall CF, et al. The effects of airway microbiome on corticosteroid responsiveness in asthma. *Am J Respir Crit Care Med.* (2013) 188:1193–201. doi: 10.1164/rccm.201304-0775OC
129. Huang YJ, Nelson CE, Brodie EL, Desantis TZ, Baek MS, Liu J, et al. Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. *J Allergy Clin Immunol.* (2011) 127:372–81.e1–3. doi: 10.1016/j.jaci.2010.10.048
130. Marri PR, Stern DA, Wright AL, Billheimer D, Martinez FD. Asthma-associated differences in microbial composition of induced sputum. *J Allergy Clin Immunol.* (2013) 131:346–52.e3. doi: 10.1016/j.jaci.2012.11.013
131. Denner DR, Sangwan N, Becker JB, Hogarth DK, Oldham J, Castillo J, et al. Corticosteroid therapy and airflow obstruction influence the bronchial microbiome, which is distinct from that of bronchoalveolar lavage in asthmatic airways. *J Allergy Clin Immunol.* (2016) 137:1398–405.e3. doi: 10.1016/j.jaci.2015.10.017
132. Polderman TJC, Benyamin B, De Leeuw CA, Sullivan PF, Van Bochoven A, Visscher PM, et al. Meta-analysis of the heritability of human traits based on fifty years of twin studies. *Nat Genet.* (2015) 47:702–9. doi: 10.1038/ng.3285
133. Thomsen SF, Duffy DL, Kyvik KO, Backer V. Genetic influence on the age at onset of asthma: a twin study. *J Allergy Clin Immunol.* (2010) 126:626–30. doi: 10.1016/j.jaci.2010.06.017
134. Morales E, Duffy D. Genetics and gene-environment interactions in childhood and adult onset asthma. *Front Pediatr.* (2019) 7:499. doi: 10.3389/fped.2019.00499
135. Vercelli D. Discovering susceptibility genes for asthma and allergy. *Nat Rev Immunol.* (2008) 8:169–82. doi: 10.1038/nri2257
136. Vicente CT, Revez JA, Ferreira MAR. Lessons from ten years of genome-wide association studies of asthma. *Clin Transl Immunol.* (2017) 6:e165. doi: 10.1038/cti.2017.54
137. Lockett GA, Holloway JW. Genome-wide association studies in asthma; perhaps, the end of the beginning. *Curr Opin Allergy Clin Immunol.* (2013) 13:463–9. doi: 10.1097/ACI.0b013e328364ea5f
138. Rava M, Smit LAM, Nadif R. Gene-environment interactions in the study of asthma in the postgenomewide association studies era. *Curr Opin Allergy Clin Immunol.* (2015) 15:70–8. doi: 10.1097/ACI.0000000000000131
139. Moffatt MF, Kabisch M, Liang L, Dixon AL, Strachan D, Heath S, et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. *Nature.* (2007) 448:470–3. doi: 10.1038/nature06014
140. Smit LAM, Bouzigon E, Pin I, Siroux V, Monier F, Aschard H, et al. 17Q21 variants modify the association between early respiratory infections and asthma. *Eur Respir J.* (2010) 36:57–64. doi: 10.1183/09031936.00154509
141. Çalişkan M, Bochkov YA, Kreiner-Møller E, Bønnelykke K, Stein MM, Du G, et al. Rhinovirus wheezing illness and genetic risk of childhood-onset asthma. *N Engl J Med.* (2013) 368:1398–407. doi: 10.1056/NEJMoa1211592
142. Zhang Y, Willis-Owen SAG, Spiegel S, Lloyd CM, Moffatt MF, Cookson, et al. The ORMDL3 asthma gene regulates ICAM1 and has multiple effects

- on cellular inflammation. *Am J Respir Crit Care Med.* (2019) 199:478–88. doi: 10.1164/rccm.201803-0438OC
143. Bønnelykke K, Sleiman P, Nielsen K, Kreiner-Møller E, Mercader JM, Belgrave D, et al. A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbations. *Nat Genet.* (2014) 46:51–5. doi: 10.1038/ng.2830
 144. Bønnelykke K, Coleman AT, Evans MD, Thorsen J, Waage J, Vissing NH, et al. Cadherin-related family member 3 genetics and rhinovirus c respiratory illnesses. *Am J Respir Crit Care Med.* (2018) 197:589–94. doi: 10.1164/rccm.201705-1021OC
 145. Lorenz E, Mira JP, Frees KL, Schwartz DA. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. *Arch Intern Med.* (2002) 162:1028–32. doi: 10.1001/archinte.162.9.1028
 146. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. *Nat Genet.* (2000) 25:187–91. doi: 10.1038/76048
 147. Teräsjarvi JT, Toivonen L, Vuononvirta J, Mertsola J, Peltola V, He Q. TLR4 polymorphism, nasopharyngeal bacterial colonization, and the development of childhood asthma: a prospective birth-cohort study in Finnish children. *Genes.* (2020) 11:1–8. doi: 10.3390/genes11070768
 148. Fagerås Böttcher M, Hmani-Aifa M, Lindström A, Jenmalm MC, Mai XM, Nilsson L, et al. A TLR4 polymorphism is associated with asthma and reduced lipopolysaccharide-induced interleukin-12(p70) responses in Swedish children. *J Allergy Clin Immunol.* (2004) 114:561–7. doi: 10.1016/j.jaci.2004.04.050
 149. Raby BA, Klimecki WT, Laprise C, Renaud Y, Faith J, Lemire M, et al. Polymorphisms in toll-like receptor 4 are not associated with asthma or atopy-related phenotypes. *Am J Respir Crit Care Med.* (2002) 166:1449–56. doi: 10.1164/rccm.200207-634OC
 150. Kotaniemi-Syrjänen A, Vainionpää R, Reijonen TM, Waris M, Korhonen K, Korppi M. Rhinovirus-induced wheezing in infancy - the first sign of childhood asthma? *J Allergy Clin Immunol.* (2003) 111:66–71. doi: 10.1067/mai.2003.33
 151. Lemanske RF, Jackson DJ, Gangnon RE, Evans MD, Li Z, Shult PA, et al. Rhinovirus illnesses during infancy predict subsequent childhood wheezing. *J Allergy Clin Immunol.* (2005) 116:571–7. doi: 10.1016/j.jaci.2005.06.024
 152. Jackson DJ, Gangnon RE, Evans MD, Roberg KA, Anderson EL, Pappas TE, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. *Am J Respir Crit Care Med.* (2008) 178:667–72. doi: 10.1164/rccm.200802-309OC
 153. Wu P, Hartert TV. Evidence for a causal relationship between respiratory syncytial virus infection and asthma. *Expert Rev Anti Infect Ther.* (2011) 9:731–45. doi: 10.1586/eri.11.92
 154. Sigurs N, Aljassim F, Kjellman B, Robinson PD, Sigurbergsson F, Bjarnason R, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. *Thorax.* (2010) 65:1045–52. doi: 10.1136/thx.2009.121582
 155. Kaiko GE, Phipps S, Angkasekwinai P, Dong C, Foster PS. NK cell deficiency predisposes to viral-induced Th2-type allergic inflammation via epithelial-derived IL-25. *J Immunol.* (2010) 185:4681–90. doi: 10.4049/jimmunol.1001758
 156. Spalluto CM, Singhanian A, Cellura D, Woelk CH, Sanchez-Elsner T, Staples KJ, et al. IFN- γ influences epithelial antiviral responses via histone methylation of the RIG-I promoter. *Am J Respir Cell Mol Biol.* (2017) 57:428–38. doi: 10.1165/rcmb.2016-0392OC
 157. Kusel MMH, de Klerk NH, Kebadze T, Vohma V, Holt PG, Johnston SL, et al. Early-life respiratory viral infections, atopic sensitization, and risk of subsequent development of persistent asthma. *J Allergy Clin Immunol.* (2007) 119:1105–10. doi: 10.1016/j.jaci.2006.12.669
 158. Rubner FJ, Jackson DJ, Evans MD, Gangnon RE, Tisler CJ, Pappas TE, et al. Early life rhinovirus wheezing, allergic sensitization, and asthma risk at adolescence. *J Allergy Clin Immunol.* (2017) 139:501–7. doi: 10.1016/j.jaci.2016.03.049
 159. Murray CS, Poletti G, Kebadze T, Morris J, Woodcock A, Johnston SL, et al. Study of modifiable risk factors for asthma exacerbations: virus infection and allergen exposure increase the risk of asthma hospital admissions in children. *Thorax.* (2006) 61:376–82. doi: 10.1136/thx.2005.042523
 160. Matsuse H, Behera AK, Kumar M, Rabb H, Lockey RF, Mohapatra SS. Recurrent respiratory syncytial virus infections in allergen-sensitized mice lead to persistent airway inflammation and hyperresponsiveness. *J Immunol.* (2000) 164:6583–92. doi: 10.4049/jimmunol.164.12.6583
 161. Woś M, Sanak M, Soja J, Olechnowicz H, Busse WW, Szczeklik A. The presence of rhinovirus in lower airways of patients with bronchial asthma. *Am J Respir Crit Care Med.* (2008) 177:1082–9. doi: 10.1164/rccm.200607-973OC
 162. Kim EY, Battaile JT, Patel AC, You Y, Agapov E, Grayson MH, et al. Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. *Nat Med.* (2008) 14:633–40. doi: 10.1038/nm1770
 163. Bønnelykke K, Vissing NH, Sevelsted A, Johnston SL, Bisgaard H. Association between respiratory infections in early life and later asthma is independent of virus type. *J Allergy Clin Immunol.* (2015) 136:81–6.e4. doi: 10.1016/j.jaci.2015.02.024
 164. Beck JM, Young VB, Huffnagle GB. The microbiome of the lung. *Transl Res.* (2012) 160:258–66. doi: 10.1016/j.trsl.2012.02.005
 165. Bisgaard H, Hermansen MN, Buchvald F, Loland L, Halkjaer LB, Bønnelykke K, et al. Childhood asthma after bacterial colonization of the airway in neonates. *N Engl J Med.* (2007) 357:1487–95. doi: 10.1056/NEJMoa052632
 166. Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. *Proc Natl Acad Sci USA.* (2010) 107:11971–5. doi: 10.1073/pnas.1002601107
 167. Reyman M, van Houten MA, van Baarle D, Bosch, AATM, Man WH, Chu MLJ, et al. Impact of delivery mode-associated gut microbiota dynamics on health in the first year of life. *Nat Commun.* (2019) 10:5352. doi: 10.1038/s41467-019-13373-1
 168. Duijts L, Jaddeo VVW, Hofman A, Moll HA. Prolonged and exclusive breastfeeding reduces the risk of infectious diseases in infancy. *Pediatrics.* (2010) 126:e18–25. doi: 10.1542/peds.2008-3256
 169. Biesbroek G, Tsvitvadze E, Sanders EAM, Montijn R, Veenhoven RH, Keijser BJE, et al. Early respiratory microbiota composition determines bacterial succession patterns and respiratory health in children. *Am J Respir Crit Care Med.* (2014) 190:1283–92. doi: 10.1164/rccm.201407-1240OC
 170. Eder W, Ege MJ, von Mutius E. The asthma epidemic. *N Engl J Med.* (2006) 355:2226–35. doi: 10.1056/NEJMra054308
 171. Adami AJ, Bracken SJ. Breathing better through bugs: asthma and the microbiome. *Yale J Biol Med.* (2016) 89:309–24.
 172. Strachan DP. Family size, infection and atopy: the first decade of the 'hygiene hypothesis'. *Thorax.* (2000) 55(Suppl. 1):S2–10. doi: 10.1136/thorax.55.suppl_1.S2
 173. Von Ehrenstein OS, Von Mutius E, Illi S, Baumann L, Böhm O, Von Kries R. Reduced risk of hay fever and asthma among children of farmers. *Clin Exp Allergy.* (2000) 30:187–93. doi: 10.1046/j.1365-2222.2000.00801.x
 174. Ege MJ, Mayer M, Normand AC, Genuneit J, Cookson OCM, Braun-Fahrlander C, Heederik D, et al. Exposure to environmental microorganisms and childhood asthma. *N Engl J Med.* (2011) 364:701–9. doi: 10.1056/NEJMoa1007302
 175. Holgate ST. Innate and adaptive immune responses in asthma. *Nat Med.* (2012) 18:673–83. doi: 10.1038/nm.2731
 176. Von Mutius E. Environmental microorganisms and lung health. *Ann Am Thorac Soc.* (2014) 11:S13–5. doi: 10.1513/AnnalsATS.201306-155MG
 177. Teo SM, Mok D, Pham K, Kusel M, Serralha M, Troy N, et al. The infant nasopharyngeal microbiome impacts severity of lower respiratory infection and risk of asthma development. *Cell Host Microbe.* (2015) 17:704–15. doi: 10.1016/j.chom.2015.03.008
 178. Bosch AATM, De Steenhuijsen Pitsers WAA, Van Houten MA, Chu MLJN, Biesbroek G, et al. Maturation of the infant respiratory microbiota, environmental drivers, and health consequences. *Am J Respir Crit Care Med.* (2017) 196:1582–90. doi: 10.1164/rccm.201703-0554OC
 179. Teo SM, Tang HHF, Mok D, Judd LM, Watts SC, Pham K, et al. Airway microbiota dynamics uncover a critical window for interplay of pathogenic bacteria and allergy in childhood respiratory disease. *Cell Host Microbe.* (2018) 24:341–52.e5. doi: 10.1016/j.chom.2018.08.005
 180. Chapman TJ, Morris MC, Xu L, Pichichero ME. Nasopharyngeal colonization with pathobionts is associated with susceptibility

- to respiratory illnesses in young children. *PLoS ONE*. (2020) 15:e0243942. doi: 10.1371/journal.pone.0243942
181. Larsen JM, Brix S, Thysen AH, Birch S, Rasmussen MA, Bisgaard H. Children with asthma by school age display aberrant immune responses to pathogenic airway bacteria as infants. *J Allergy Clin Immunol*. (2014) 133:1008–13.e4. doi: 10.1016/j.jaci.2014.01.010
 182. McCann JR, Mason SN, Auten RL, St. Geme JW, Seed PC. Early-life intranasal colonization with nontypeable *Haemophilus influenzae* exacerbates juvenile airway disease in mice. *Infect Immun*. (2016) 84:2022–30. doi: 10.1128/IAI.01539-15
 183. Alnahas S, Hagner S, Raifer H, Kilic A, Gasteiger G, Mutters R, et al. IL-17 and TNF- α are key mediators of *Moraxella catarrhalis* triggered exacerbation of allergic airway inflammation. *Front Immunol*. (2017) 8:1562. doi: 10.3389/fimmu.2017.01562
 184. Martin E, Treiner E, Duban L, Guerri L, Laude H, Toly C, et al. Stepwise development of MAIT cells in mouse and human. *PLoS Biol*. (2009) 7:e1000054. doi: 10.1371/journal.pbio.1000054
 185. Treiner E, Duban L, Bahram S, Radosavljevic M, Wanner V, Tilloy F, et al. Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. *Nature*. (2003) 422:164–69. doi: 10.1038/nature01433
 186. Wallington JC, Williams AP, Staples KJ, Wilkinson TMA. IL-12 and IL-7 synergize to control mucosal-associated invariant T-cell cytotoxic responses to bacterial infection. *J Allergy Clin Immunol*. (2018) 141:2182–95.e6. doi: 10.1016/j.jaci.2017.08.009
 187. Dumas A, Corral D, Colom A, Levillain F, Peixoto A, Hudrisier D, et al. The host microbiota contributes to early protection against lung colonization by *Mycobacterium tuberculosis*. *Front Immunol*. (2018) 14:2656. doi: 10.3389/fimmu.2018.02656
 188. Meierovics A, Yankelevich, W.-J. C., Cowley SC. MAIT cells are critical for optimal mucosal immune responses during *in vivo* pulmonary bacterial infection. *Proc Natl Acad Sci USA*. (2013) 110:E3119–28. doi: 10.1073/pnas.1302799110
 189. Mayhew D, Devos N, Lambert C, Brown JR, Clarke SC, Kim VL, et al. Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations. *Thorax*. (2018) 73:422–30. doi: 10.1136/thoraxjnl-2017-210408
 190. Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. *Nat Rev Immunol*. (2016) 16:341–52. doi: 10.1038/nri.2016.42
 191. Franzosa EA, Morgan XC, Segata N, Waldron L, Reyes J, Earl AM, et al. Relating the metatranscriptome and metagenome of the human gut. *Proc Natl Acad Sci USA*. (2014) 111:E2329–38. doi: 10.1073/pnas.1319284111
 192. Castro-Nallar E, Shen Y, Freishtat RJ, Pérez-Losada M, Manimaran S, Liu G, et al. Integrating microbial and host transcriptomics to characterize asthma-associated microbial communities. *BMC Med Genomics*. (2015) 8:50. doi: 10.1186/s12920-015-0121-1
 193. Pérez-Losada M, Castro-Nallar E, Bendall ML, Freishtat RJ, Crandall KA. Dual transcriptomic profiling of host and microbiota during health and disease in pediatric asthma. *PLoS ONE*. (2015) 10:e0131819. doi: 10.1371/journal.pone.0131819
 194. Følsgaard NV, Schjørring S, Chawes BL, Rasmussen MA, Krogfelt KA, Brix S, et al. Pathogenic bacteria colonizing the airways in asymptomatic neonates stimulates topical inflammatory mediator release. *Am J Respir Crit Care Med*. (2013) 187:589–95. doi: 10.1164/rccm.201207-1297OC
 195. Simpson JL, Phipps S, Baines KJ, Oreo KM, Gunawardhana L, Gibson PG. Elevated expression of the NLRP3 inflammasome in neutrophilic asthma. *Eur Respir J*. (2014) 43:1067–76. doi: 10.1183/09031936.00105013
 196. Essilfie AT, Simpson JL, Horvat JC, Preston JA, Dunkley ML, Foster PS, et al. *Haemophilus influenzae* infection drives IL-17-mediated neutrophilic allergic airways disease. *PLoS Pathog*. (2011) 7:e1002244. doi: 10.1371/journal.ppat.1002244
 197. Essilfie AT, Simpson JL, Dunkley ML, Morgan LC, Oliver BG, Gibson PG, et al. Combined *Haemophilus influenzae* respiratory infection and allergic airways disease drives chronic infection and features of neutrophilic asthma. *Thorax*. (2012) 67:588–99. doi: 10.1136/thoraxjnl-2011-200160
 198. Yang X, Wang Y, Zhao S, Wang R, Wang C. Long-term exposure to low-dose *Haemophilus influenzae* during allergic airway disease drives a steroid-resistant neutrophilic inflammation and promotes airway remodeling. *Oncotarget*. (2018) 9:24898–13. doi: 10.18632/oncotarget.24653
 199. Busse WW, Holgate S, Kerwin E, Chon Y, Feng J, Lin J, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. *Am J Respir Crit Care Med*. (2013) 188:1294–302. doi: 10.1164/rccm.201212-2318OC
 200. Baines KJ, Simpson JL, Wood LG, Scott RJ, Gibson PG. Transcriptional phenotypes of asthma defined by gene expression profiling of induced sputum samples. *J Allergy Clin Immunol*. (2011) 127:153–60.e9. doi: 10.1016/j.jaci.2010.10.024
 201. Hastie AT, Moore WC, Meyers DA, Vestal PL, Li H, Peters SP, et al. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. *J Allergy Clin Immunol*. (2010) 125:1028–36.e13. doi: 10.1016/j.jaci.2010.02.008
 202. Hernandez ML, Mills K, Almond M, Todoric K, Aleman MM, Zhang H, et al. IL-1 receptor antagonist reduces endotoxin-induced airway inflammation in healthy volunteers. *J Allergy Clin Immunol*. (2015) 135:379–85. doi: 10.1016/j.jaci.2014.07.039
 203. Kalchier-Dekel O, Yao X, Levine SJ. Meeting the challenge of identifying new treatments for type 2-low neutrophilic asthma. *Chest*. (2020) 157:26–33. doi: 10.1016/j.chest.2019.08.2192
 204. Nair P, Gaga M, Zervas E, Alagha K, Hargreave FE, O'Byrne PM, et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. *Clin Exp Allergy*. (2012) 42:1097–103. doi: 10.1111/j.1365-2222.2012.04014.x
 205. O'Byrne PM, Metev H, Puu M, Richter K, Keen C, Uddin M, et al. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. *Lancet Respir Med*. (2016) 4:797–806. doi: 10.1016/S2213-2600(16)30227-2
 206. Higgins D, Trujillo C, Keech C. Advances in RSV vaccine research and development - a global agenda. *Vaccine*. (2016) 34:2870–5. doi: 10.1016/j.vaccine.2016.03.109
 207. Wilkinson TMA, Schembri S, Brightling C, Bakerly ND, Lewis K, MacNee W, et al. Non-typeable *Haemophilus influenzae* protein vaccine in adults with COPD: a phase 2 clinical trial. *Vaccine*. (2019) 37:6102–11. doi: 10.1016/j.vaccine.2019.07.100
 208. Van Damme P, Leroux-Roels G, Vandermeulen C, De Ryck I, Tasciotti A, Dozot M, et al. Safety and immunogenicity of non-typeable *Haemophilus influenzae-Moraxella catarrhalis* vaccine. *Vaccine*. (2019) 37:3113–22. doi: 10.1016/j.vaccine.2019.04.041
 209. Watson A, Wilkinson TMA. Respiratory viral infections in the elderly. *Therap Adv Respir Dis*. (2021) 15:1753466621995050. doi: 10.1177/1753466621995050
 210. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. *Nat Rev Drug Discov*. (2018) 17:261–79. doi: 10.1038/nrd.2017.243
 211. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. *N Engl J Med*. (2020) 383:2603–15. doi: 10.1056/NEJMoa2034577
 212. Sánchez-Ramón S, Conejero L, Netea MG, Sancho D, Palomares Ó, Subiza JL. Trained immunity-based vaccines: a new paradigm for the development of broad-spectrum anti-infectious formulations. *Front Immunol*. (2018) 9:2936. doi: 10.3389/fimmu.2018.02936
 213. Roth M, Pasquali C, Stolz D, Tamm M. (2017). Broncho Vaxom (OM-85) modulates rhinovirus docking proteins on human airway epithelial cells via Erk1/2 mitogen activated protein kinase and cAMP. *PLoS ONE*. 12:e0188010. doi: 10.1371/journal.pone.0188010
 214. Coviello S, Wimmenauer V, Polack FP, Irusta PM. Bacterial lysates improve the protective antibody response against respiratory viruses through Toll-like receptor 4. *Hum Vaccines Immunother*. (2014) 10:2896–02. doi: 10.4161/hv.29784
 215. de Boer GM, Zólkiewicz J, Strzelec KP, Ruszczynski M, Hendriks RW, Braunstahl GJ, Feleszko W, et al. Bacterial lysate therapy for the prevention of wheezing episodes and asthma exacerbations: a systematic review and meta-analysis. *Eur Respir Rev*. (2020) 29:190175. doi: 10.1183/16000617.0175-2019
 216. Ahmadzizadeh F, Vijverberg SJH, Arets HGM, de Boer A, Turner S, Devereux G, et al. Early life antibiotic use and the risk of asthma and

- asthma exacerbations in children. *Pediatr Allergy Immunol.* (2017) 28:430–7. doi: 10.1111/pai.12725
217. Toivonen L, Schuez-Havupalo L, Karppinen S, Waris M, Hoffman KL, Camargo CA, et al. Antibiotic treatments during infancy, changes in nasal microbiota, and asthma development: population-based cohort study. *Clin Infect Dis.* (2021) 72:1546–54. doi: 10.1093/cid/ciaa262
218. Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, et al. Efficacy of azithromycin in severe asthma from the AMAZES randomised trial. *ERJ Open Res.* (2019) 5:00056–2019. doi: 10.1183/23120541.00056-2019
219. Taylor SL, Leong LEX, Mobegi FM, Choo JM, Wesselingh S, Yang IA, et al. Long-term azithromycin reduces *Haemophilus influenzae* and increases antibiotic resistance in severe asthma. *Am J Respir Crit Care Med.* (2019) 200:309–17. doi: 10.1164/rccm.201809-1739OC
220. Valery PC, Morris PS, Byrnes CA, Grimwood K, Torzillo PJ, Bauert PA, et al. Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial. *Lancet Respir.* (2013) 1:610–20. doi: 10.1016/S2213-2600(13)70185-1
221. Essilfie AT, Horvat JC, Kim RY, Mayall JR, Pinkerton JW, Beckett EL, et al. Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid-insensitive asthma. *Thorax.* (2015) 70:458–67. doi: 10.1136/thoraxjnl-2014-206067
222. Hodge S, Tran HB, Hamon R, Roscioli E, Hodge G, Jersmann H, et al. Nonantibiotic macrolides restore airway macrophage phagocytic function with potential anti-inflammatory effects in chronic lung diseases. *Am J Physiol Lung Cell Mol Physiol.* (2017) 312:L678–87. doi: 10.1152/ajplung.00518.2016
223. Nicholas B, Staples KJ, Moese S, Meldrum E, Ward J, Dennison P, et al. A novel lung explant model for the *ex vivo* study of efficacy and mechanisms of anti-influenza drugs. *J Immunol.* (2015) 194:6144–54. doi: 10.4049/jimmunol.1402283
224. Watson A, Madsen J, Clark HW. SP-A and SP-D: dual functioning immune molecules with antiviral and immunomodulatory properties. *Front Immunol.* (2021) 11:3692. doi: 10.3389/fimmu.2020.622598
225. Littlejohn JR, da Silva RF, Neale WA, Smallcombe CC, Clark HW, Mackay R-MA, et al. Structural definition of hSP-D recognition of *Salmonella enterica* LPS inner core oligosaccharides reveals alternative binding modes for the same LPS. *PLoS ONE.* (2018) 13:e0199175. doi: 10.1371/journal.pone.0199175
226. Nayak A, Dodagatta-Marri E, Tsolaki AG, Kishore UP. An insight into the diverse roles of surfactant proteins, SP-A and SP-D in innate and adaptive immunity. *Front Immunol.* (2012) 3:131. doi: 10.3389/fimmu.2012.00131
227. Fakh D, Pilecki B, Schlosser A, Jepsen CS, Thomsen LK, Ormhoj M, et al. Protective effects of surfactant protein D treatment in 1,3- β -glucan-modulated allergic inflammation. *Am J Physiol Lung Cell Mol Physiol.* (2015) 309:L1333–43. doi: 10.1152/ajplung.00090.2015
228. Watson A, Sorensen GL, Holmskov U, Whitwell HJ, Madsen J, Clark H. Generation of novel trimeric fragments of human SP-A and SP-D after recombinant soluble expression in *E. coli*. *Immunobiology.* (2020) 225:151953. doi: 10.1016/j.imbio.2020.151953
229. Staples KJ, Taylor S, Thomas S, Leung S, Cox K, Pascal TG, et al. Relationships between mucosal antibodies, non-typeable *Haemophilus influenzae* (NTHi) infection and airway inflammation in COPD. *PLoS ONE.* (2016) 11:e0167250. doi: 10.1371/journal.pone.0167250
230. Beech AS, Lea S, Kolsum U, Wang Z, Miller BE, Donaldson GC, et al. Bacteria and sputum inflammatory cell counts; a COPD cohort analysis. *Respir Res.* (2020) 21:289. doi: 10.1186/s12931-020-01552-4
231. Osei ET, Brandsma C, Timens W, Heijink IH, Hackett T. Current perspectives on the role of interleukin-1 signalling in the pathogenesis of asthma and COPD. *Eur Respir J.* (2020) 55:1900563. doi: 10.1183/13993003.00563-2019
232. Deonarain R, Alcamí A, Alexiou M, Dallman MJ, Gewert DR, Porter AC. Impaired antiviral response and alpha/beta interferon induction in mice lacking beta interferon. *J Virol.* (2000) 74:3404–9. doi: 10.1128/JVI.74.7.3404-3409.2000
233. Koerner I, Kochs G, Kalinke U, Weiss S, Staeheli P. Protective role of beta interferon in host defense against influenza A virus. *J Virol.* (2007) 81:2025–30. doi: 10.1128/JVI.01718-06
234. Staples KJ, Nicholas B, McKendry RT, Spalluto CM, Wallington JC, Bragg CW, et al. Viral infection of human lung macrophages increases PDL1 expression via IFN β . *PLoS ONE.* (2015) 10:e0121527. doi: 10.1371/journal.pone.0121527
235. Djukanović R, Harrison T, Johnston SL, Gabbay F, Wark P, Thomson NC, et al. The effect of inhaled IFN- β on worsening of asthma symptoms caused by viral infections: a randomized trial. *Am J Respir Crit Care Med.* (2014) 190:145–54. doi: 10.1164/rccm.201312-2235OC
236. McCrae C, Olsson M, Gustafson P, Malmgren A, Aurell M, Fagerås M, et al. INEXAS: a phase 2 randomized trial of on-demand inhaled interferon beta-1a in severe asthmatics. *Clin Exp Allergy.* (2021) 51:273–83. doi: 10.1111/cea.13765
237. Deonarain R, Alcamí A, Alexiou M, Dallman MJ, Gewert DR, Porter AC. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Respir Med.* (2021) 9:196–206. doi: 10.1016/S2213-2600(20)30511-7
238. Watson A, Spalluto CM, McCrae C, Cellura D, Burke H, Cunoosamy D, et al. Dynamics of IFN- β responses during respiratory viral infection insights for therapeutic strategies. *Am J Respir Crit Care Med.* (2020) 201:83–94. doi: 10.1164/rccm.201901-0214OC
239. Ichinohe T, Pang IK, Kumamoto Y, Peaper DR, Ho JH, Murray TS, et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. *Proc Natl Acad Sci USA.* (2011) 108:5354–9. doi: 10.1073/pnas.1019378108
240. Abt MC, Osborne LC, Monticelli LA, Doering TA, Alenghat T, Sonnenberg GE, et al. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. *Immunity.* (2012) 37:158–70. doi: 10.1016/j.immuni.2012.04.011
241. Preidis GA, Versalovic J. Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. *Gastroenterology.* (2009) 136:2015–31. doi: 10.1053/j.gastro.2009.01.072
242. Herbst T, Sichelstiel A, Schär C, Yadava K, Bürki K, Cahenzli J, et al. Dysregulation of allergic airway inflammation in the absence of microbial colonization. *Am J Respir Crit Care Med.* (2011) 184:198–205. doi: 10.1164/rccm.201010-1574OC
243. Remot A, Descamps D, Noordine ML, Boukadiri A, Mathieu E, Robert V, et al. Bacteria isolated from lung modulate asthma susceptibility in mice. *ISME J.* (2017) 11:1061–74. doi: 10.1038/ismej.2016.181
244. Kanmani P, Clua P, Vizoso-Pinto MG, Rodriguez C, Alvarez S, Melnikov V, et al. Respiratory commensal bacteria *Corynebacterium pseudodiphtheriticum* improves resistance of infant mice to respiratory syncytial virus and *Streptococcus pneumoniae* superinfection. *Front Microbiol.* (2017) 8:1613. doi: 10.3389/fmicb.2017.01613
245. Deasy AM, Guccione E, Dale AP, Andrews N, Evans CM, Bennett JS, et al. Nasal inoculation of the commensal *Neisseria lactamica* inhibits carriage of *Neisseria meningitidis* by young adults: a controlled human infection study. *Clin Infect Dis.* (2015) 60:1512–20. doi: 10.1093/cid/civ098
246. Thorsen J, Rasmussen MA, Waage J, Mortensen M, Brejnrod A, Bonnelykke K, et al. Infant airway microbiota and topical immune perturbations in the origins of childhood asthma. *Nat Commun.* (2019) 10:5001. doi: 10.1038/s41467-019-12989-7
247. van Tilburg Bernardes E, Gutierrez MW, Arrieta MC. The fungal microbiome and asthma. *Front Cell Infect Microbiol.* (2020) 10:736. doi: 10.3389/fcimb.2020.583418
248. Sharma A, Laxman B, Naureckas ET, Hogarth DK, Sperling AI, Solway J, et al. Associations between fungal and bacterial microbiota of airways and asthma endotypes. *J Allergy Clin Immunol.* (2019) 144:1214–27.e7. doi: 10.1016/j.jaci.2019.06.025
249. Stern DA, Morgan WJ, Halonen M, Wright AL, Martinez FD. Wheezing and bronchial hyper-responsiveness in early childhood as predictors of newly diagnosed asthma in early adulthood: a longitudinal birth-cohort study. *Lancet.* (2008) 372:1058–64. doi: 10.1016/S0140-6736(08)61447-6
250. Liu HY, Li CX, Liang ZY, Zhang SY, Yang WY, Ye YM, et al. The interactions of airway bacterial and fungal communities in clinically stable asthma. *Front Microbiol.* (2020) 11:1647. doi: 10.3389/fmicb.2020.01647

Conflict of Interest: KS reports grants from AstraZeneca outside the conduct of the study. TW reports grants and personal fees from AstraZeneca, personal fees

and other from MMH, grants and personal fees from GSK, grants and personal fees from AZ, personal fees from BI, grants and personal fees from Synairgen, outside the submitted work.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of

the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Ackland, Watson, Wilkinson and Staples. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.